Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Liver Diseases

Free Subscription Articles published in Hepatology Retrieve available abstracts of 568 articles: HTML format

Single Articles

September 2025
1. DELTENRE P, Marot A, Henrion J
   A prognostic model in patients with alcohol-related cirrhosis does exist.
   Hepatology. 2025 Sep 17. doi: 10.1097/HEP.0000000000001532.
   PubMed    
   
   
   
2. PAN Z
   Letter to the editor: Technical considerations in the development of a multimodal deep learning model for predicting hepatocellular carcinoma outcomes.
   Hepatology. 2025 Sep 17. doi: 10.1097/HEP.0000000000001534.
   PubMed    
   
   
   
3. LIU TH, Yang HC
   Letter to the Editor: Clarifying the impact of response criteria and locoregional therapy on complete response outcomes in patients with hepatocellular carcinoma following immunotherapy.
   Hepatology. 2025 Sep 4. doi: 10.1097/HEP.0000000000001459.
   PubMed    
   
   
   
4. ZHANG L, Li H, Zong W, Li B, et al
   Letter to the Editor: Revisiting FOXP3 Expression and its prognostic implications in hepatocellular carcinoma.
   Hepatology. 2025 Sep 3. doi: 10.1097/HEP.0000000000001512.
   PubMed    
   
   
   
5. HUANG CH, Ku WT, Wu TH, Lin PT, et al
   Reply to the Letter to the Editor: Revisiting FOXP3 expression and its prognostic implications in hepatocellular carcinoma.
   Hepatology. 2025 Sep 3. doi: 10.1097/HEP.0000000000001515.
   PubMed    
   
   
   
6. LAI JC, Tapper E, Tandon P
   Integrative hepatology: Enhancing overall health to manage liver disease.
   Hepatology. 2025 Sep 3. doi: 10.1097/HEP.0000000000001516.
   PubMed     Abstract available
   
   
   
7. JEONG JM, Choi SE, Shim YR, Kim HH, et al
   CX3CR1+ macrophages interact with HSCs to promote HCC through CD8+ T-cell suppression.
   Hepatology. 2025;82:655-668.
   PubMed     Abstract available
   
   
   
8. LI W, Chi Y, Xiao X, Li J, et al
   Plasma FSTL-1 as a noninvasive diagnostic biomarker for patients with advanced liver fibrosis.
   Hepatology. 2025;82:669-682.
   PubMed     Abstract available
   
   
   
9. YANG Y, Ni Q, Li H, Sun J, et al
   Genomic and the tumor microenvironment heterogeneity in multifocal hepatocellular carcinoma.
   Hepatology. 2025;82:582-598.
   PubMed     Abstract available
   
   
   
10. ZHOU KQ, Zhong YC, Song MF, Sun YF, et al
    Distinct immune microenvironment of venous tumor thrombus in hepatocellular carcinoma at single-cell resolution.
    Hepatology. 2025;82:566-581.
    PubMed     Abstract available
    
    
    
11. SINGAL AG, Quirk L, Boike J, Chernyak V, et al
    Value of HCC surveillance in a landscape of emerging surveillance options: Perspectives of a multi-stakeholder modified Delphi panel.
    Hepatology. 2025;82:794-809.
    PubMed     Abstract available
    
    
    
12. PANG Z, Zhang H, Zheng S, Yang X, et al
    HNF4alpha-CDKL3 axis restricts MASLD progression by targeting FoxO1 via noncanonical phosphorylation.
    Hepatology. 2025;82:702-721.
    PubMed     Abstract available
    
    
    
13. FACCIOLI LAP, Sun Y, Animasahun O, Motomura T, et al
    Human-induced pluripotent stem cell-based hepatic modeling of lipid metabolism-associated TM6SF2-E167K variant.
    Hepatology. 2025;82:638-654.
    PubMed     Abstract available
    
    
    
14. ERICKSON H
    Hepatic stellate cells and macrophages: Key players in HCC immune suppression.
    Hepatology. 2025;82:545-546.
    PubMed    
    
    
    
15. WILECHANSKY RM
    Surging sludge: Intrahepatic cholangiocarcinoma mortality on the rise worldwide.
    Hepatology. 2025;82:543-544.
    PubMed    
    
    
    
16. ZHANGYUAN G, Yu W, Tian W, Xie J, et al
    RIPPLY1 suppresses cancer cell stemness via targeting TBX19 in CTNNB1-mutated hepatocellular carcinoma.
    Hepatology. 2025 Sep 1. doi: 10.1097/HEP.0000000000001483.
    PubMed     Abstract available
    
    
    
17. SUN Y, Chen S, Xu X, Piao H, et al
    Early on-treatment LSM reliably predicts liver-related events in CHB patients with significant fibrosis and cirrhosis.
    Hepatology. 2025 Sep 1. doi: 10.1097/HEP.0000000000001504.
    PubMed     Abstract available
    
    
    August 2025
18. HILSCHER MB
    The pressure is on: Elucidating hemodynamic profiles associated with esophageal varices in the Fontan circulation.
    Hepatology. 2025 Aug 26. doi: 10.1097/HEP.0000000000001510.
    PubMed    
    
    
    
19. ANANIA FA, Hager R, Higgins K, Makar GA, et al
    Non-Invasive Tests: Establishing efficacy for metabolic dysfunction associated steatohepatitis beyond the biopsy-current perspectives from the division of hepatology and nutrition, US Food and Drug Administration.
    Hepatology. 2025 Aug 26. doi: 10.1097/HEP.0000000000001509.
    PubMed     Abstract available
    
    
    
20. DING J, She HY, Cheng Y, Sun HY, et al
    A novel mechanism involving USP53-regulated BSEP trafficking underlies low-GGT intrahepatic cholestasis.
    Hepatology. 2025 Aug 19. doi: 10.1097/HEP.0000000000001501.
    PubMed     Abstract available
    
    
    
21. ZHOU SL, Yin D, Hu ZQ, Luo CB, et al
    Erratum: A positive feedback loop between cancer stem-like cells and tumor-associated neutrophils controls hepatocellular carcinoma progression.
    Hepatology. 2025 Aug 14. doi: 10.1097/HEP.0000000000001476.
    PubMed    
    
    
    
22. JOHN BV, Bastaich DR, Deng Y, Singal AG, et al
    Use of liver stiffness measurement for hepatocellular carcinoma risk stratification in metabolic dysfunction associated steatotic liver disease.
    Hepatology. 2025 Aug 14. doi: 10.1097/HEP.0000000000001498.
    PubMed     Abstract available
    
    
    
23. INDRE MG, Leucuta DC, Lupsor-Platon M, Turco L, et al
    Diagnostic accuracy of 2D-SWE ultrasound for liver fibrosis assessment in MASLD: A multilevel random effects model meta-analysis.
    Hepatology. 2025;82:454-469.
    PubMed     Abstract available
    
    
    
24. LOH JJ, Ng KY, Huang IB, Deng M, et al
    DGKH-mediated phosphatidic acid oncometabolism as a driver of self-renewal and therapy resistance in HCC.
    Hepatology. 2025;82:308-325.
    PubMed     Abstract available
    
    
    
25. DRIESSEN S, Francque SM, Anker SD, Castro Cabezas M, et al
    Metabolic dysfunction-associated steatotic liver disease and the heart.
    Hepatology. 2025;82:487-503.
    PubMed     Abstract available
    
    
    
26. SU T, Huang M, Liao J, Lin S, et al
    Erratum: Insufficient radiofrequency ablation promotes hepatocellular carcinoma metastasis through N6-methyladenosine mRNA methylation-dependent mechanism.
    Hepatology. 2025;82:E35-E36.
    PubMed    
    
    
    July 2025
27. ACUNA-PILARTE K, Reichert EC, Green YS, Halberg LM, et al
    Erratum: HAF prevents hepatocyte apoptosis and progression to MASH and HCC through transcriptional regulation of the NF-kappaB pathway.
    Hepatology. 2025 Jul 30. doi: 10.1097/HEP.0000000000001416.
    PubMed    
    
    
    
28. FAN G, Han X, Shi Y
    Reply: Reevaluating PCA and SCTransform usage in single-cell intrahepatic cholangiocarcinoma analysis.
    Hepatology. 2025 Jul 30. doi: 10.1097/HEP.0000000000001480.
    PubMed    
    
    
    
29. TAKEFUJI Y
    Letter to the editor: Reevaluating PCA and SCTransform usage in single-cell intrahepatic cholangiocarcinoma analysis.
    Hepatology. 2025 Jul 29. doi: 10.1097/HEP.0000000000001479.
    PubMed    
    
    
    
30. APODAKA-BIGURI M, Simao AL, Gonzalez-Romero F, Mestre D, et al
    E2F2 transcription factor promotes a cholestatic MASH phenotype by regulating hepatobiliary metabolism through miR-34a-5p.
    Hepatology. 2025 Jul 28. doi: 10.1097/HEP.0000000000001461.
    PubMed     Abstract available
    
    
    
31. NAKIB D, MacParland S
    Decoding the PSC fibrotic niche: Hepatocyte stress and metallothioneins.
    Hepatology. 2025 Jul 25. doi: 10.1097/HEP.0000000000001478.
    PubMed    
    
    
    
32. HUANG Q, Wang W, Ge Q, Xu D, et al
    NEK7 induced phosphorylation of EGFR on serine 1070 drive the acquired lenvatinib resistance in hepatocellular carcinoma.
    Hepatology. 2025 Jul 22. doi: 10.1097/HEP.0000000000001474.
    PubMed     Abstract available
    
    
    
33. SEIF EL DAHAN K, Daher D, Rich NE, Nayak AJ, et al
    Causes of mortality among patients with early-stage hepatocellular carcinoma.
    Hepatology. 2025 Jul 22. doi: 10.1097/HEP.0000000000001471.
    PubMed     Abstract available
    
    
    
34. TELLEZ L, Toledano M, Alvarez M, Garrido-Lestache E, et al
    Distinctive hemodynamic phenotype in Fontan-type circulation patients with distal esophageal varices.
    Hepatology. 2025 Jul 22. doi: 10.1097/HEP.0000000000001472.
    PubMed     Abstract available
    
    
    
35. ABRUZZESE GA, Martinez-Chantar ML
    Minor players, major signals: Unveiling the systemic and gut-localized impact of microbial amidated bile acids in hepatopancreatobiliary disease.
    Hepatology. 2025 Jul 21. doi: 10.1097/HEP.0000000000001473.
    PubMed    
    
    
    
36. BAJAJ JS, Reddy KR, Tandon P, Lai JC, et al
    Salivary microbiome and serum metabolomics add to clinical biomarkers to predict 6-month hospitalizations in a multi-center cirrhosis outpatient cohort.
    Hepatology. 2025 Jul 9. doi: 10.1097/HEP.0000000000001462.
    PubMed     Abstract available
    
    
    
37. SCHEINER B, Pinter M
    Reply: Clarifying the impact of response criteria and locoregional therapy on complete response outcomes in patients with hepatocellular carcinoma following immunotherapy.
    Hepatology. 2025 Jul 7. doi: 10.1097/HEP.0000000000001460.
    PubMed    
    
    
    
38. SU TH, Shin EC
    Peripheral blood Foxp3-High tregs: A novel prognostic biomarker in hepatocellular carcinoma.
    Hepatology. 2025 Jul 7. doi: 10.1097/HEP.0000000000001464.
    PubMed    
    
    
    
39. SINHA S, Ali Q, Zhang T, T-Nguyen DH, et al
    Aging disrupts hepatocyte zonation homeostasis in mice and humans.
    Hepatology. 2025 Jul 4. doi: 10.1097/HEP.0000000000001451.
    PubMed     Abstract available
    
    
    
40. GUO Y, Zhang Q, Li B, Dai W, et al
    Biliary YB-1/GLI2 axis facilitates ductular reaction and promotes hepatic stellate cell activation via SPP1/Integrin alphavbeta1 signaling during liver fibrogenesis.
    Hepatology. 2025 Jul 4. doi: 10.1097/HEP.0000000000001458.
    PubMed     Abstract available
    
    
    
41. CHONG LUGON N, Rabiee A, Mezzacappa C, Kaplan DE, et al
    Prognostic significance of mild ascites in patients with cirrhosis.
    Hepatology. 2025 Jul 3. doi: 10.1097/HEP.0000000000001452.
    PubMed     Abstract available
    
    
    
42. TRAUNER M, Karpen SJ, Dawson PA
    Benefits and challenges to therapeutic targeting of bile acid circulation in cholestatic liver disease.
    Hepatology. 2025 Jul 2. doi: 10.1097/HEP.0000000000001438.
    PubMed     Abstract available
    
    
    
43. UNTALAN M, A Crimmins N, Yates KP, A Mencin A, et al
    Prevalence of subclinical hypothyroidism and longitudinal thyroid-stimulating hormone changes in youth with metabolic dysfunction-associated steatotic liver disease: An observational study.
    Hepatology. 2025;82:155-164.
    PubMed     Abstract available
    
    
    
44. SALIBA-GUSTAFSSON P, Justesen JM, Ranta A, Sharma D, et al
    A functional genomic framework to elucidate novel causal metabolic dysfunction-associated fatty liver disease genes.
    Hepatology. 2025;82:165-183.
    PubMed     Abstract available
    
    
    
45. HAI S, Li X, Xie E, Wu W, et al
    Intestinal IL-33 promotes microbiota-derived trimethylamine N -oxide synthesis and drives metabolic dysfunction-associated steatotic liver disease progression by exerting dual regulation on HIF-1alpha.
    Hepatology. 2025;82:184-198.
    PubMed     Abstract available
    
    
    
46. DIAZ LA, Winder GS, Leggio L, Bajaj JS, et al
    New insights into the molecular basis of alcohol abstinence and relapse in alcohol-associated liver disease.
    Hepatology. 2025;82:254-271.
    PubMed     Abstract available
    
    
    
47. ADLAT S, Vazquez Salgado AM, Lee M, Yin D, et al
    Emerging and potential use of CRISPR in human liver disease.
    Hepatology. 2025;82:232-253.
    PubMed     Abstract available
    
    
    
48. HUANG CH, Ku WT, Mahalingam J, Wu CH, et al
    Tumor-migrating peripheral Foxp3-high regulatory T cells drive poor prognosis in hepatocellular carcinoma.
    Hepatology. 2025 Jul 1. doi: 10.1097/HEP.0000000000001428.
    PubMed     Abstract available
    
    
    
49. XU X, Li H, Lin H, Li Q, et al
    MIF-mediated crosstalk between THRSP+ hepatocytes and CD74+ lipid-associated macrophages in hepatic periportal zone drives MASH.
    Hepatology. 2025 Jul 1. doi: 10.1097/HEP.0000000000001429.
    PubMed     Abstract available
    
    
    June 2025
50. NAM H, Kim DY, Kim DY, Kim JH, et al
    Development and validation of a risk prediction model for patients with hepatocellular carcinoma receiving atezolizumab-bevacizumab.
    Hepatology. 2025 Jun 30. doi: 10.1097/HEP.0000000000001444.
    PubMed     Abstract available
    
    
    
51. ZHANG L, Han C, Shrestha MM, Le J, et al
    The OGT-TFF2 axis mediates intrahepatic crosstalk and MASH pathogenesis.
    Hepatology. 2025 Jun 30. doi: 10.1097/HEP.0000000000001445.
    PubMed     Abstract available
    
    
    
52. XIAOFANG S, Zhanhui O, Ruochan C, Xiaohua N, et al
    Erratum: Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells.
    Hepatology. 2025 Jun 25. doi: 10.1097/HEP.0000000000001384.
    PubMed    
    
    
    
53. LI J, Xu L, Rui F, Tran S, et al
    Type 2 Diabetes mellitus as an independent predictor of significant fibrosis in treatment-naive chronic hepatitis B patients with concurrent hepatic steatosis.
    Hepatology. 2025 Jun 25. doi: 10.1097/HEP.0000000000001442.
    PubMed     Abstract available
    
    
    
54. YANG DL, Ye L, Zeng FJ, Liu J, et al
    Erratum: Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in
    Hepatology. 2025 Jun 25. doi: 10.1097/HEP.0000000000001401.
    PubMed    
    
    
    
55. TEMPRANO AG, Romero MR, Ghallab A, Llera L, et al
    Gut-to-Bile transfer of microbially amidated minor bile acids in patients with hepatopancreatobiliary disorders.
    Hepatology. 2025 Jun 23. doi: 10.1097/HEP.0000000000001441.
    PubMed     Abstract available
    
    
    
56. TAO J, Wang J
    Reply: Considerations on the specific role of LHX2 in the process of hepatic stellate cells regulating hepatocyte function.
    Hepatology. 2025 Jun 18. doi: 10.1097/HEP.0000000000001435.
    PubMed    
    
    
    
57. NI J, Zhai D, Li J, Li B, et al
    Letter to editor: Considerations on the specific role of LHX2 in the process of hepatic stellate cells regulating hepatocyte function.
    Hepatology. 2025 Jun 16. doi: 10.1097/HEP.0000000000001434.
    PubMed    
    
    
    
58. SU JY, Li JR, Pan LX, Ma YL, et al
    Tertiary lymphoid structures in hepatocellular carcinoma: Influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy.
    Hepatology. 2025 Jun 11. doi: 10.1097/HEP.0000000000001433.
    PubMed     Abstract available
    
    
    
59. SHAW J, Acharya C, Fagan A, Olofson A, et al
    Health IT interventions reduce avoidable readmissions in cirrhosis: The HEROIC randomized controlled trial.
    Hepatology. 2025 Jun 11. doi: 10.1097/HEP.0000000000001424.
    PubMed     Abstract available
    
    
    
60. LI F, Li Y, Wang L, Xu L, et al
    Tumor microenvironment heterogeneity and progression mechanisms in intrahepatic cholangiocarcinoma: A study based on single-cell and spatial transcriptomic sequencing.
    Hepatology. 2025 Jun 9. doi: 10.1097/HEP.0000000000001423.
    PubMed     Abstract available
    
    
    
61. PEDDU DK, Tedesco N, Rutledge SM, Wijarnpreecha K, et al
    Social determinants of health influence the risk of cirrhosis: A diverse nationwide cohort study.
    Hepatology. 2025 Jun 9. doi: 10.1097/HEP.0000000000001420.
    PubMed     Abstract available
    
    
    
62. BIAN Q, Wang S, Song Z, Liu F, et al
    Arid1a deficiency promotes hepatocyte hyperpolyploidy and drives intrahepatic cholangiocarcinoma in mice.
    Hepatology. 2025 Jun 9. doi: 10.1097/HEP.0000000000001422.
    PubMed     Abstract available
    
    
    
63. WANG H, Wang S, Lei Y, Chen Y, et al
    Serum amyloid A1-Induced intrahepatic regulatory T cell dysfunction drives autoimmune hepatitis progression.
    Hepatology. 2025 Jun 9. doi: 10.1097/HEP.0000000000001419.
    PubMed     Abstract available
    
    
    
64. MANDORFER M, Jachs M, Semmler G
    Roadmap for a generally accepted model to predict first hepatic decompensation in compensated advanced chronic liver disease.
    Hepatology. 2025 Jun 9. doi: 10.1097/HEP.0000000000001431.
    PubMed    
    
    
    
65. LIANG BG, Zheng YM, Xu MH, Gao C, et al
    The MASTL/YBX1/PAK4 axis regulated by stress-activated STK24 triggers lenvatinib resistance and tumor progression in hepatocellular carcinoma.
    Hepatology. 2025 Jun 2. doi: 10.1097/HEP.0000000000001392.
    PubMed     Abstract available
    
    
    
66. TINCOPA MA, Diaz LA, Huang DQ, Arab JP, et al
    Disparities in screening and risk stratification for Hispanic adults with metabolic dysfunction-associated steatotic liver disease.
    Hepatology. 2025;81:1792-1804.
    PubMed     Abstract available
    
    
    
67. MARINO Z, Garcia-Sola C, Rios J, Bono A, et al
    Exchangeable copper for patients with Wilson disease at follow-up: Rethinking normal ranges or changing methodology.
    Hepatology. 2025;81:1728-1739.
    PubMed     Abstract available
    
    
    
68. FAN L, Tian C, Yang W, Liu X, et al
    HKDC1 promotes liver cancer stemness under hypoxia through stabilizing beta-catenin.
    Hepatology. 2025;81:1685-1699.
    PubMed     Abstract available
    
    
    
69. BAKRANIA A, Mo Y, Zheng G, Bhat M, et al
    RNA nanomedicine in liver diseases.
    Hepatology. 2025;81:1847-1877.
    PubMed     Abstract available
    
    
    
70. MACHIDA K, Tsukamoto H, Liu JC, Han YP, et al
    Retraction: C-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair.
    Hepatology. 2025;81:E181.
    PubMed    
    
    
    
71. JIANG JX, Fish SR, Tomilov A, Li Y, et al
    Erratum: Nonphagocytic activation of NOX2 is implicated in progressive nonalcoholic steatohepatitis during aging.
    Hepatology. 2025;81:E180.
    PubMed    
    
    
    
72. HARRIS K
    LPCN 1148: Rebuilding muscle memory in cirrhosis patients.
    Hepatology. 2025;81:1625-1626.
    PubMed    
    
    
    
73. EISWERTH M, Arab JP
    A new voice in diagnosing and predicting hepatic encephalopathy.
    Hepatology. 2025;81:1623-1624.
    PubMed    
    
    
    May 2025
74. NGUYEN T, Shin Y, Ruppa A, Krall AS, et al
    Galectin-1 modulates glycolysis via a GM1-galactose-dependent pathway to promote hyperthermia resistance in hepatocellular carcinoma.
    Hepatology. 2025 May 21. doi: 10.1097/HEP.0000000000001391.
    PubMed     Abstract available
    
    
    
75. XIE L, Chen H, Zhang L, Yang YY, et al
    Suppressing MASH fibrotic progression by blocking succinate-GPR91 signaling in hepatic stellate cells.
    Hepatology. 2025 May 19. doi: 10.1097/HEP.0000000000001405.
    PubMed     Abstract available
    
    
    
76. REGHUPATY SC, Raha S, Mendoza R, Manna D, et al
    TATA-box binding protein associated factor 2 (TAF2) in hepatocyte survival and tumorigenesis.
    Hepatology. 2025 May 19. doi: 10.1097/HEP.0000000000001406.
    PubMed     Abstract available
    
    
    
77. LAU G, Sangro B, Cheng AL, Kudo M, et al
    Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trial.
    Hepatology. 2025 May 16. doi: 10.1097/HEP.0000000000001385.
    PubMed     Abstract available
    
    
    
78. JIN Y, Wang M, Xu A, Xu B, et al
    Letter to the Editor: Association between mean arterial pressure and terlipressin in the reversal of hepatorenal syndrome-acute kidney injury.
    Hepatology. 2025 May 15. doi: 10.1097/HEP.0000000000001404.
    PubMed    
    
    
    
79. WANG Y, Yang L, Li M, Hao J, et al
    Proenkephalin produced by neonatal T-bet+ Treg cells promotes periportal hepatocyte maturation.
    Hepatology. 2025 May 12. doi: 10.1097/HEP.0000000000001389.
    PubMed     Abstract available
    
    
    
80. WANG C, Dong D, Zhao N, Zhao S, et al
    Hepatocyte-specific C-C motif chemokine ligand 9 signaling promotes liver fibrosis progression in mice.
    Hepatology. 2025 May 9. doi: 10.1097/HEP.0000000000001393.
    PubMed     Abstract available
    
    
    
81. YANG DL, Li YF, Li YJ, Qiu GG, et al
    Reply: Survival benefit of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors as conversion therapy for unresectable hepatocellular carcinoma needs more details.
    Hepatology. 2025 May 9. doi: 10.1097/HEP.0000000000001395.
    PubMed    
    
    
    
82. YU TC, Zhao L, Sze KM, Tian L, et al
    GPD1L supports glycerol-3-phosphate and triacylglycerol synthesis and promotes tumor progression in hepatocellular carcinoma.
    Hepatology. 2025 May 9. doi: 10.1097/HEP.0000000000001394.
    PubMed     Abstract available
    
    
    
83. GENG Y, Schwabe RF
    Hepatic stellate cell heterogeneity: Functional aspects and therapeutic implications.
    Hepatology. 2025 May 8. doi: 10.1097/HEP.0000000000001386.
    PubMed     Abstract available
    
    
    
84. O'ROURKE CJ, Andersen JB
    Intrahepatic Cholangiocarcinoma PANoptosidy.
    Hepatology. 2025 May 8. doi: 10.1097/HEP.0000000000001398.
    PubMed    
    
    
    
85. WANG D, Yi S, Liu X
    Letter to the editor: Survival benefit of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors as conversion therapy for unresectable hepatocellular carcinoma needs more details.
    Hepatology. 2025 May 8. doi: 10.1097/HEP.0000000000001390.
    PubMed    
    
    
    
86. YANG Z, Jiang Y, Ma J, Wang L, et al
    LncRNA H19 promoted alcohol-associated liver disease through dysregulation of alternative splicing and methionine metabolism.
    Hepatology. 2025;81:1485-1500.
    PubMed     Abstract available
    
    
    
87. SUN Y, Wei H, Yu W, Gao H, et al
    The actin-binding protein drebrin disrupts NF2-LATS kinases complex assembly to facilitate liver tumorigenesis.
    Hepatology. 2025;81:1433-1451.
    PubMed     Abstract available
    
    
    
88. ZHANG S, Yan Y, Zeng XF, Gu Y, et al
    Associations of the EAT-Lancet reference diet with metabolic dysfunction-associated steatotic liver disease and its severity: A multicohort study.
    Hepatology. 2025;81:1583-1594.
    PubMed     Abstract available
    
    
    
89. HUANG DQ, Wilson LA, Behling C, Amangurbanova M, et al
    Liver stiffness progression in biopsy-proven metabolic dysfunction-associated steatotic disease among people with diabetes versus people without diabetes: A prospective multicenter study.
    Hepatology. 2025;81:1553-1563.
    PubMed     Abstract available
    
    
    
90. OLUBAMIWA AO, Liao TJ, Zhao J, Dehanne P, et al
    Drug interaction with UDP-Glucuronosyltransferase (UGT) enzymes is a predictor of drug-induced liver injury.
    Hepatology. 2025;81:1512-1521.
    PubMed     Abstract available
    
    
    
91. MONIAUX N, Geoffre N, Deshayes A, Dos Santos A, et al
    Tumor suppressive role of the antimicrobial lectin REG3A targeting the O -GlcNAc glycosylation pathway.
    Hepatology. 2025;81:1416-1432.
    PubMed     Abstract available
    
    
    
92. NOVOA E, da Silva Lima N, Gonzalez-Rellan MJ, Chantada-Vazquez MDP, et al
    Mitochondrial antiviral signaling protein enhances MASLD progression through the ERK/TNFalpha/NFkappabeta pathway.
    Hepatology. 2025;81:1535-1552.
    PubMed     Abstract available
    
    
    
93. DE RUDDER M, Manco R, Coubeau L, Fontaine A, et al
    Vascular damage and excessive proliferation compromise liver function after extended hepatectomy in mice.
    Hepatology. 2025;81:1468-1484.
    PubMed     Abstract available
    
    
    
94. NORDEN-KRICHMAR TM, Rotroff D, Schwantes-An TH, Bataller R, et al
    Genomic approaches to explore susceptibility and pathogenesis of alcohol use disorder and alcohol-associated liver disease.
    Hepatology. 2025;81:1595-1606.
    PubMed     Abstract available
    
    
    
95. CHAGANTI J, Zeng G, Patil A, Lockart I, et al
    Altered blood-brain barrier permeability is associated with abnormal distant connectivity and regional homogeneity in covert hepatic encephalopathy - a cross sectional study.
    Hepatology. 2025 May 1. doi: 10.1097/HEP.0000000000001343.
    PubMed     Abstract available
    
    
    
96. ZHANG Q, Song Q, Liu Y, Li J, et al
    Letter to the Editor: Redefining post-resection care: Critical analysis of adjuvant TACE in curative hepatocellular carcinoma management.
    Hepatology. 2025 May 1. doi: 10.1097/HEP.0000000000001327.
    PubMed    
    
    
    April 2025
97. YAO J, Liu P, Teng X, Kong D, et al
    Alcohol-induced disruption of hepatic m6A modification exacerbates alcohol-associated steatohepatitis by impairing liver immune microenvironment homeostasis.
    Hepatology. 2025 Apr 30. doi: 10.1097/HEP.0000000000001374.
    PubMed     Abstract available
    
    
    
98. FUJIWARA N, Matsushita Y, Tempaku M, Tachi Y, et al
    AI-based phenotyping of hepatic fiber morphology to inform molecular alterations in metabolic dysfunction-associated steatotic liver disease.
    Hepatology. 2025 Apr 22. doi: 10.1097/HEP.0000000000001360.
    PubMed     Abstract available
    
    
    
99. FIX OK, Kane M, Gainey CS, Khairat S, et al
    Privacy and fidelity: The promise of synthetic data in hepatology research.
    Hepatology. 2025 Apr 21. doi: 10.1097/HEP.0000000000001361.
    PubMed    
    
    
    
100. WANG J, Zhang S, Fan T, Wu C, et al
     Letter to the Editor: Association of hepatitis B surface antigen and risk of hepatocellular carcinoma in chronic hepatitis B patients with immune-tolerant phase.
     Hepatology. 2025 Apr 21. doi: 10.1097/HEP.0000000000001365.
     PubMed    
     
     
     
101. HUI VW, Wong GL, Dai J, Tse YK, et al
     Increased risk of hepatocellular carcinoma in HBeAg-negative indeterminate phase compared to HBeAg-negative chronic infection.
     Hepatology. 2025 Apr 21. doi: 10.1097/HEP.0000000000001354.
     PubMed     Abstract available
     
     
     
102. TSENG TC, Kao JH
     Reply: Association of hepatitis B surface antigen and risk of hepatocellular carcinoma in chronic hepatitis B patients with immune-tolerant phase.
     Hepatology. 2025 Apr 21. doi: 10.1097/HEP.0000000000001366.
     PubMed    
     
     
     
103. HOLMER M, Ingre M, Farkkila M, Ponsioen C, et al
     Cirrhosis and age are key determinants of HCC risk in individuals with primary sclerosing cholangitis: A multicenter longitudinal cohort study.
     Hepatology. 2025 Apr 16. doi: 10.1097/HEP.0000000000001351.
     PubMed     Abstract available
     
     
     
104. YU Y, You Y, Duan Y, Kang M, et al
     Multiomics approaches for identifying the PANoptosis signature and prognostic model via a multimachine-learning computational framework for intrahepatic cholangiocarcinoma.
     Hepatology. 2025 Apr 15. doi: 10.1097/HEP.0000000000001352.
     PubMed     Abstract available
     
     
     
105. ROCCARINA D, Saltini D, Senzolo M, Nardelli S, et al
     Reply: Post-TIPS hemodynamic target adherence fails to improve outcomes in cirrhotic patients.
     Hepatology. 2025 Apr 8. doi: 10.1097/HEP.0000000000001350.
     PubMed    
     
     
     
106. TANTAI X, Li L, Dai S
     Letter to the editor: Considerations on the use of LPCN 1148 in cirrhotic patients with sarcopenia.
     Hepatology. 2025 Apr 8. doi: 10.1097/HEP.0000000000001347.
     PubMed    
     
     
     
107. TANTAI X, Li L, Dai S
     Letter to the editor: Post-TIPS hemodynamic target adherence fails to improve outcomes in cirrhotic patients.
     Hepatology. 2025 Apr 8. doi: 10.1097/HEP.0000000000001349.
     PubMed    
     
     
     
108. BRUNO BJ, Weavil JC, Ogle J, Chidambaram N, et al
     Reply: Considerations on the use of LPCN 1148 in cirrhotic patients with sarcopenia.
     Hepatology. 2025 Apr 8. doi: 10.1097/HEP.0000000000001348.
     PubMed    
     
     
     
109. YANG LX, Gao Q, Shi JY, Wang ZC, et al
     Erratum: Mitogen-activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial-mesenchymal transition.
     Hepatology. 2025 Apr 7. doi: 10.1097/HEP.0000000000001274.
     PubMed    
     
     
     
110. LAI JC, Lok AS
     Accurate prediction of hepatocellular carcinoma risk in patients with chronic HBV infection: HBeAg status and HBsAg level matter.
     Hepatology. 2025 Apr 3. doi: 10.1097/HEP.0000000000001345.
     PubMed    
     
     
     
111. WANG B, Hsu SH, Wang X, Kutay H, et al
     Erratum: Reciprocal regulation of microRNA-122 and c-Myc in hepatocellular cancer: Role of E2F1 and transcription factor dimerization partner 2.
     Hepatology. 2025 Apr 3. doi: 10.1097/HEP.0000000000001261.
     PubMed    
     
     
     
112. NOBEL YR, Boike JR, Mazumder NR, Thornburg B, et al
     Predictors of long-term clinical outcomes after TIPS: An ALTA group study.
     Hepatology. 2025;81:1244-1255.
     PubMed     Abstract available
     
     
     
113. OJHA U, Kim S, Rhee CY, You J, et al
     Endothelial RUNX3 controls LSEC dysfunction and angiocrine LRG1 signaling to prevent liver fibrosis.
     Hepatology. 2025;81:1228-1243.
     PubMed     Abstract available
     
     
     
114. LEFERE S, Mosca A, Hudert C, Dupont E, et al
     Development and validation of pFIB scores for exclusion of significant liver fibrosis in pediatric MASLD.
     Hepatology. 2025;81:1276-1287.
     PubMed     Abstract available
     
     
     
115. HLADY RA, Zhao X, El Khoury LY, Wagner RT, et al
     Epigenetic heterogeneity hotspots in human liver disease progression.
     Hepatology. 2025;81:1197-1210.
     PubMed     Abstract available
     
     
     
116. STALLER DW, Panigrahi SS, Jayasinghe YP, Dong Y, et al
     A novel phosphodiesterase inhibitor for the treatment of chronic liver injury and metabolic diseases.
     Hepatology. 2025;81:1288-1303.
     PubMed     Abstract available
     
     
     
117. ZANUSO V, Rimassa L, Braconi C
     The rapidly evolving landscape of HCC: Selecting the optimal systemic therapy.
     Hepatology. 2025;81:1365-1386.
     PubMed     Abstract available
     
     
     
118. KUREBAYASHI Y, Sakamoto M
     Macrotrabecular hepatocellular carcinoma: Unique immunovascular characteristics.
     Hepatology. 2025 Apr 1. doi: 10.1097/HEP.0000000000001339.
     PubMed    
     
     
     
119. MOL B, Werner E, Culver EL, van der Meer AJ, et al
     Epidemiological and economical burden of cholestatic liver disease.
     Hepatology. 2025 Apr 1. doi: 10.1097/HEP.0000000000001341.
     PubMed     Abstract available
     
     
     March 2025
120. AHN JC, Ng WH, Yeo YH, Kim HS, et al
     Comparative effectiveness of immunotherapy versus lenvatinib in advanced hepatocellular carcinoma: A real-world analysis using target trial emulation.
     Hepatology. 2025 Mar 28. doi: 10.1097/HEP.0000000000001328.
     PubMed     Abstract available
     
     
     
121. GUO Y, Wang J, Zhang L, Shen S, et al
     Erratum: Theranostical nanosystem-mediated identification of an oncogene and highly effective therapy in hepatocellular carcinoma.
     Hepatology. 2025 Mar 27. doi: 10.1097/HEP.0000000000001240.
     PubMed    
     
     
     
122. KIM KE, Lee J, Shin HJ, Jeong EA, et al
     Erratum: Lipocalin-2 activates hepatic stellate cells and promotes nonalcoholic steatohepatitis in high-fat diet-fed Ob/Ob mice.
     Hepatology. 2025 Mar 27. doi: 10.1097/HEP.0000000000001287.
     PubMed    
     
     
     
123. MACIAS RIR, Roessler S, Verstegen MMA
     Deciphering the spatial tumor microenvironment in intrahepatic cholangiocarcinoma.
     Hepatology. 2025 Mar 24. doi: 10.1097/HEP.0000000000001322.
     PubMed    
     
     
     
124. SU R, Tao X, Yan L, Liu Y, et al
     Early screening, diagnosis and recurrence monitoring of hepatocellular carcinoma in chronic hepatitis B patients based on serum N-glycomics analysis: A cohort study.
     Hepatology. 2025 Mar 21. doi: 10.1097/HEP.0000000000001316.
     PubMed     Abstract available
     
     
     
125. TSENG TC, Hosaka T, Pan MH, Liu CJ, et al
     Higher level of Hepatitis B Surface antigen associated with delayed development of hepatocellular carcinoma in immune-tolerant patients.
     Hepatology. 2025 Mar 20. doi: 10.1097/HEP.0000000000001313.
     PubMed     Abstract available
     
     
     
126. WONG CC, Wong CM
     CAD-Driven pathways in hepatocellular carcinoma metastasis.
     Hepatology. 2025 Mar 19. doi: 10.1097/HEP.0000000000001315.
     PubMed    
     
     
     
127. CHEN S, Shen L, Fan W
     Letter to the Editor: The divergences in the efficacy of adjuvant transarterial chemoembolization for hepatocellular carcinoma: In-depth analysis and enlightenments.
     Hepatology. 2025 Mar 18. doi: 10.1097/HEP.0000000000001310.
     PubMed    
     
     
     
128. ZHANG T, Huang CJ, Chen HT, Huang YH, et al
     HLA-DQB1*03:01 and risk of Hepatitis B virus-related hepatocellular carcinoma.
     Hepatology. 2025 Mar 14. doi: 10.1097/HEP.0000000000001307.
     PubMed     Abstract available
     
     
     
129. ZHAO Q, Liu H, Yang Z, Han X, et al
     Pre-B-Cell leukemia transcription factor 1 contributes to liver fibrosis by enabling IL-7 signaling in hepatic stellate cells.
     Hepatology. 2025 Mar 13. doi: 10.1097/HEP.0000000000001302.
     PubMed     Abstract available
     
     
     
130. PAN J, Zhang M, Rao D, Ma J, et al
     CAD manipulates tumor intrinsic DHO/UBE4B/NF-kappaB pathway and fuels macrophage cross-talk, promoting hepatocellular carcinoma metastasis.
     Hepatology. 2025 Mar 12. doi: 10.1097/HEP.0000000000001304.
     PubMed     Abstract available
     
     
     
131. MONTAGNESE S, Duarte-Rojo A
     Hepatic encephalopathy - We are no longer those who believe that reality is what we perceive.
     Hepatology. 2025 Mar 12. doi: 10.1097/HEP.0000000000001308.
     PubMed    
     
     
     
132. LI PJ, Tabrizian P, Daher D, Gaviria F, et al
     A prospective multicenter validation of RETREAT for post-transplantation hepatocellular carcinoma recurrence prediction.
     Hepatology. 2025 Mar 11. doi: 10.1097/HEP.0000000000001297.
     PubMed     Abstract available
     
     
     
133. AHN JC, Noh YK, Hu M, Shen X, et al
     AI-driven synthetic data generation for accelerating hepatology research: A study of the United Network for Organ Sharing (UNOS) database.
     Hepatology. 2025 Mar 11. doi: 10.1097/HEP.0000000000001299.
     PubMed     Abstract available
     
     
     
134. WANG P, Zhong L
     Letter to the Editor: Downstaging of hepatocellular carcinoma before liver transplantation: More details, more significance.
     Hepatology. 2025 Mar 10. doi: 10.1097/HEP.0000000000001301.
     PubMed    
     
     
     
135. XU E, Mehta N
     Reply: Downstaging of hepatocellular carcinoma before liver transplantation.
     Hepatology. 2025 Mar 10. doi: 10.1097/HEP.0000000000001303.
     PubMed    
     
     
     
136. CULLARO G, Allegretti AS, Patidar KR, Jamil K, et al
     The relationship between mean arterial pressure and terlipressin in hepatorenal syndrome-acute kidney injury reversal: a post hoc analysis.
     Hepatology. 2025 Mar 7. doi: 10.1097/HEP.0000000000001295.
     PubMed     Abstract available
     
     
     
137. SUN Y, Li T, Ding L, Wang J, et al
     Platelet-mediated circulating tumor cell evasion from natural killer cell killing through immune checkpoint CD155-TIGIT.
     Hepatology. 2025;81:791-807.
     PubMed     Abstract available
     
     
     
138. NAKATSUKA T, Tateishi R, Sato M, Hashizume N, et al
     Deep learning and digital pathology powers prediction of HCC development in steatotic liver disease.
     Hepatology. 2025;81:976-989.
     PubMed     Abstract available
     
     
     
139. SASAKI K, Rooge S, Gunewardena S, Hintz JA, et al
     Kupffer cell diversity maintains liver function in alcohol-associated liver disease.
     Hepatology. 2025;81:870-887.
     PubMed     Abstract available
     
     
     
140. HAN S, Fan H, Zhong G, Ni L, et al
     Nuclear KRT19 is a transcriptional corepressor promoting histone deacetylation and liver tumorigenesis.
     Hepatology. 2025;81:808-822.
     PubMed     Abstract available
     
     
     
141. KIM D, Shah M, Kim JH, Kim J, et al
     Integrative transcriptomic and genomic analyses unveil the IFI16 variants and expression as MASLD progression markers.
     Hepatology. 2025;81:962-975.
     PubMed     Abstract available
     
     
     
142. LIU LZ, Zhang Z, Zheng BH, Shi Y, et al
     Erratum: CCL15 recruits suppressive monocytes to facilitate immune escape and disease progression in hepatocellular carcinoma.
     Hepatology. 2025;81:E113-E114.
     PubMed    
     
     
     
143. DHANASEKARAN R, Suzuki H, Lemaitre L, Kubota N, et al
     Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision-making.
     Hepatology. 2025;81:1038-1057.
     PubMed     Abstract available
     
     
     February 2025
144. TANIAI T, Shimada S, Akiyama Y, Hatano M, et al
     Integrative transcriptome profiling elucidates molecular and immunovascular characteristics of macrotrabecular hepatocellular carcinoma.
     Hepatology. 2025 Feb 26. doi: 10.1097/HEP.0000000000001284.
     PubMed     Abstract available
     
     
     
145. VOLKERT I, Grube J, Woitok MM, Mohamed MR, et al
     Selective genetic inactivation of Caspase 8 in hepatocytes ameliorates progression of MASH following Jnk deficiency.
     Hepatology. 2025 Feb 26. doi: 10.1097/HEP.0000000000001286.
     PubMed     Abstract available
     
     
     
146. LIAO W, Zhang Y, Wang J, Cui G, et al
     beta-Catenin regulates distinct pathways from YAP and suppresses ONECUT1 to drive hepatoblastoma development in mice and humans.
     Hepatology. 2025 Feb 25. doi: 10.1097/HEP.0000000000001280.
     PubMed     Abstract available
     
     
     
147. HONG L, Mei J, Sun X, Wu Y, et al
     Spatial single-cell proteomics landscape decodes the tumor microenvironmental ecosystem of intrahepatic cholangiocarcinoma.
     Hepatology. 2025 Feb 25. doi: 10.1097/HEP.0000000000001283.
     PubMed     Abstract available
     
     
     
148. CARDOSO FS
     Letter to the Editor: Mean arterial pressure as a complex treatment target in patients with cirrhosis and acute kidney injury.
     Hepatology. 2025 Feb 25. doi: 10.1097/HEP.0000000000001288.
     PubMed    
     
     
     
149. TADDEI TH, Brown DB, Yarchoan M, Mendiratta-Lala M, et al
     Critical Update: AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.
     Hepatology. 2025 Feb 24. doi: 10.1097/HEP.0000000000001269.
     PubMed    
     
     
     
150. WANG ZC, Gao Q, Shi JY, Guo WJ, et al
     Erratum: Protein tyrosine phosphatase receptor S acts as a metastatic suppressor in hepatocellular carcinoma by control of epithermal growth factor receptor-induced epithelial-mesenchymal transition.
     Hepatology. 2025 Feb 18. doi: 10.1097/HEP.0000000000001176.
     PubMed    
     
     
     
151. WONG GL, Chan HL
     Divergent trends in cirrhosis and liver cancer highlight the ongoing efforts required for hepatitis elimination.
     Hepatology. 2025 Feb 18. doi: 10.1097/HEP.0000000000001273.
     PubMed    
     
     
     
152. CANCADO GGL, Deeb M, Gulamhusein AF
     Liver transplantation for cholestatic liver diseases: Timing & disease recurrence.
     Hepatology. 2025 Feb 17. doi: 10.1097/HEP.0000000000001268.
     PubMed     Abstract available
     
     
     
153. LEE EW, Saab S, Eghbalieh N, Ding PX, et al
     Coil or Plug-Assisted Retrograde transvenous obliteration (CARTO/PARTO) for treating portal hypertensive variceal bleeding: A multi-center, real-world 10-year retrospective study.
     Hepatology. 2025 Feb 5. doi: 10.1097/HEP.0000000000001255.
     PubMed     Abstract available
     
     
     
154. SOUZA M, Al-Sharif L, Antunes VLJ, Huang DQ, et al
     Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis.
     Hepatology. 2025 Feb 4. doi: 10.1097/HEP.0000000000001254.
     PubMed     Abstract available
     
     
     
155. BURTIS AEC, DeNicola DMC, Ferguson ME, Santos RG, et al
     Ag-driven CD8 + T cell clonal expansion is a prominent feature of MASH in humans and mice.
     Hepatology. 2025;81:591-608.
     PubMed     Abstract available
     
     
     
156. MOGA L, Paradis V, Ferreira-Silva J, Gudavalli K, et al
     Performance of spleen stiffness measurement to rule out high-risk varices in patients with porto-sinusoidal vascular disorder.
     Hepatology. 2025;81:546-559.
     PubMed     Abstract available
     
     
     
157. EL-SERAG HB, Jin Q, Tayob N, Salem E, et al
     HES V2.0 outperforms GALAD for detection of HCC: A phase 3 biomarker study in the United States.
     Hepatology. 2025;81:465-475.
     PubMed     Abstract available
     
     
     
158. FEIO-AZEVEDO R, Boesch M, Radenkovic S, van Melkebeke L, et al
     Distinct immunometabolic signatures in circulating immune cells define disease outcome in acute-on-chronic liver failure.
     Hepatology. 2025;81:509-522.
     PubMed     Abstract available
     
     
     
159. WONG YJ, Chen VL, Abdulhamid A, Tosetti G, et al
     Comparing serial and current liver stiffness measurements to predict decompensation in compensated advanced chronic liver disease patients.
     Hepatology. 2025;81:523-531.
     PubMed     Abstract available
     
     
     
160. DUARTE-ROJO A, Taouli B, Leung DH, Levine D, et al
     Imaging-based noninvasive liver disease assessment for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline.
     Hepatology. 2025;81:725-748.
     PubMed     Abstract available
     
     
     
161. MARINO L, Kim A, Ni B, Celi FS, et al
     Thyroid hormone action and liver disease, a complex interplay.
     Hepatology. 2025;81:651-669.
     PubMed     Abstract available
     
     
     January 2025
162. ZHANG Z, Zhang Z, Zhang Y, Li Y, et al
     Phosphoproteomics delineates hepatocellular carcinoma subtypes and pinpoints therapeutic targets.
     Hepatology. 2025 Jan 31. doi: 10.1097/HEP.0000000000001250.
     PubMed     Abstract available
     
     
     
163. LIU Q, Li J, Chen H, Song J, et al
     Letter to the Editor: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment.
     Hepatology. 2025 Jan 31. doi: 10.1097/HEP.0000000000001215.
     PubMed    
     
     
     
164. YOUNOSSI ZM, de Avila L, Racila A, Nader F, et al
     Prevalence and predictors of cirrhosis and portal hypertension in the united states.
     Hepatology. 2025 Jan 29. doi: 10.1097/HEP.0000000000001243.
     PubMed     Abstract available
     
     
     
165. CHENG K, Cai N, Yang X, Li D, et al
     Short-term starvation boosts anti-PD-L1 therapy by reshaping tumor-associated macrophages in hepatocellular carcinoma.
     Hepatology. 2025 Jan 29. doi: 10.1097/HEP.0000000000001244.
     PubMed     Abstract available
     
     
     
166. DESPLATS V, Haudebourg L, Verger N, Assaraf J, et al
     Acute encephalopathy without hyperammonemia has a different presentation than overt hepatic encephalopathy and displays similarly severe prognosis.
     Hepatology. 2025 Jan 29. doi: 10.1097/HEP.0000000000001252.
     PubMed     Abstract available
     
     
     
167. SEO DH, Sung PS
     Reply: Intrahepatic immunoglobulin a complex induces polarization of cancer-associated fibroblasts to matrix phenotypes in the tumor microenvironment of hepatocellular carcinoma_reply.
     Hepatology. 2025 Jan 28. doi: 10.1097/HEP.0000000000001253.
     PubMed    
     
     
     
168. LU Z, Wong CM
     The impact of LRP4 mutations on hepatocellular carcinoma recurrence and immunotherapy response.
     Hepatology. 2025 Jan 16. doi: 10.1097/HEP.0000000000001235.
     PubMed    
     
     
     
169. YANG DL, Ye L, Zeng FJ, Liu J, et al
     Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermedi
     Hepatology. 2025 Jan 15. doi: 10.1097/HEP.0000000000001229.
     PubMed     Abstract available
     
     
     
170. XU E, Tabrizian P, Gutierrez J, Hoteit M, et al
     Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multi-center prospective cohort study.
     Hepatology. 2025 Jan 14. doi: 10.1097/HEP.0000000000001231.
     PubMed     Abstract available
     
     
     
171. MA T, Bai X, Zhang Q, Chen W, et al
     Adjuvant transarterial chemoembolization for hepatocellular carcinoma following curative resection: A randomized, open-label, phase 3 trial.
     Hepatology. 2025 Jan 14. doi: 10.1097/HEP.0000000000001233.
     PubMed     Abstract available
     
     
     
172. LIU D, Chen L, Wang Z, Li Z, et al
     Ubiquitination of TFEB increased intestinal permeability to aggravate metabolic dysfunction-associated steatohepatitis.
     Hepatology. 2025 Jan 10. doi: 10.1097/HEP.0000000000001214.
     PubMed     Abstract available
     
     
     
173. OBRADOVIC F, Vitello DJ, Hasjim BJ, Obayemi J, et al
     Comparing the cost of cirrhosis to other common chronic diseases: A longitudinal study in a large national insurance database.
     Hepatology. 2025 Jan 6. doi: 10.1097/HEP.0000000000001206.
     PubMed     Abstract available
     
     
     
174. ROCCARINA D, Saltini D, Adotti V, Rosi M, et al
     End-procedural adherence to recommended hemodynamic targets does not improve the outcome of elective tips in cirrhotic patients.
     Hepatology. 2025 Jan 3. doi: 10.1097/HEP.0000000000001224.
     PubMed     Abstract available
     
     
     
175. KABELITZ MA, Hartl L, Schaub G, Tiede A, et al
     Identification of optimal portal pressure decrease to control ascites while minimizing hepatic encephalopathy after TIPS: A multicenter study.
     Hepatology. 2025 Jan 3. doi: 10.1097/HEP.0000000000001219.
     PubMed     Abstract available
     
     
     
176. RONCA V, Davies SP, Oo YH, Lleo A, et al
     The immunological landscape of primary biliary cholangitis: Mechanisms and therapeutic prospects.
     Hepatology. 2025 Jan 3. doi: 10.1097/HEP.0000000000001225.
     PubMed     Abstract available
     
     
     
177. KWAK M, Kim HS, Jiang ZG, Yeo YH, et al
     MASLD/MetALD and mortality in individuals with any cardio-metabolic risk factor: A population-based study with 26.7 years of follow-up.
     Hepatology. 2025;81:228-237.
     PubMed     Abstract available
     
     
     
178. HOBEIKA C, Ronot M, Guiu B, Ferraioli G, et al
     Ultrasound-based steatosis grading system using 2D-attenuation imaging: An individual patient data meta-analysis with external validation.
     Hepatology. 2025;81:212-227.
     PubMed     Abstract available
     
     
     
179. KE C, Xiao C, Li J, Wu X, et al
     FMO2 ameliorates nonalcoholic fatty liver disease by suppressing ER-to-Golgi transport of SREBP1.
     Hepatology. 2025;81:181-197.
     PubMed     Abstract available
     
     
     
180. 
     Erratum: Expression and functional significance of Twist1 in hepatocellular carcinoma: Its role in vasculogenic mimicry.
     Hepatology. 2025;81:E26-E27.
     PubMed    
     
     
     
181. WILECHANSKY RM
     Putting mean arterial pressure on the map as an AKI biomarker in cirrhosis.
     Hepatology. 2025;81:3-4.
     PubMed    
     
     
     December 2024
182. CELSA C, Cabibbo G, Pinato DJ
     Reply: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment.
     Hepatology. 2024 Dec 25. doi: 10.1097/HEP.0000000000001217.
     PubMed    
     
     
     
183. SUN R, Liu K, Pan S, Ye Y, et al
     LRP4 mutations promote tumour progression and resistance to anti-PD-1 therapy in recurrent hepatocellular carcinoma.
     Hepatology. 2024 Dec 24. doi: 10.1097/HEP.0000000000001212.
     PubMed     Abstract available
     
     
     
184. MA S, Chen J, Li J
     Letter to the editor: Intrahepatic immunoglobulin A complex induces polarization of cancer-associated fibroblasts to matrix phenotypes in the tumor microenvironment of hepatocellular carcinoma.
     Hepatology. 2024 Dec 23. doi: 10.1097/HEP.0000000000001197.
     PubMed    
     
     
     
185. TAO J, Wu Z, Liang Y, Wang J, et al
     Lhx2 specifically expressed in hepatic stellate cells promotes liver regeneration and inhibits liver fibrosis.
     Hepatology. 2024 Dec 18. doi: 10.1097/HEP.0000000000001201.
     PubMed     Abstract available
     
     
     
186. VUTIEN P, Barnard Giustini A, Kim NJ, Moon AM, et al
     Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death.
     Hepatology. 2024 Dec 17. doi: 10.1097/HEP.0000000000001183.
     PubMed     Abstract available
     
     
     
187. YANG Y, Ni Q, Li H, Sun J, et al
     Genomic and the tumor microenvironment heterogeneity in multifocal hepatocellular carcinoma.
     Hepatology. 2024 Dec 12. doi: 10.1097/HEP.0000000000001191.
     PubMed     Abstract available
     
     
     
188. ZHOU KQ, Zhong YC, Song MF, Sun YF, et al
     Distinct immune microenvironment of venous tumor thrombus in hepatocellular carcinoma at single-cell resolution.
     Hepatology. 2024 Dec 10. doi: 10.1097/HEP.0000000000001182.
     PubMed     Abstract available
     
     
     
189. CONDE DE LA ROSA L, Fabrega L, Torres S, Nunez S, et al
     Stard1 promotes cholestatic liver injury and disease progression by sensitizing to bile acid hepatotoxicity.
     Hepatology. 2024 Dec 9. doi: 10.1097/HEP.0000000000001184.
     PubMed     Abstract available
     
     
     
190. GONZALEZ-RECIO I, Goikoetxea-Usandizaga N, Rejano-Gordillo CM, Conter C, et al
     Modulatory effects of CNNM4 on Protein-L-Isoaspartyl-O-Methyltransferase repair function during Alcohol-Induced hepatic damage.
     Hepatology. 2024 Dec 6. doi: 10.1097/HEP.0000000000001156.
     PubMed     Abstract available
     
     
     
191. BROOKHART MA, Mayne TJ, Coombs C, Breskin A, et al
     Hepatic real-world outcomes with obeticholic acid in primary biliary cholangitis (HEROES): A trial emulation study design.
     Hepatology. 2024 Dec 2. doi: 10.1097/HEP.0000000000001174.
     PubMed     Abstract available
     
     
     
192. HUI RW, Chiu KW, Lee IC, Wang C, et al
     Multimodal multiphasic pre-operative image-based deep-learning predicts hepatocellular carcinoma outcomes after curative surgery.
     Hepatology. 2024 Dec 2. doi: 10.1097/HEP.0000000000001180.
     PubMed     Abstract available
     
     
     
193. SENGUPTA S, Gill V, Mellinger JL
     Alcohol-associated liver disease and public health policies.
     Hepatology. 2024;80:1323-1341.
     PubMed     Abstract available
     
     
     
194. HAQUE LY, Leggio L
     Integrated and collaborative care across the spectrum of alcohol-associated liver disease and alcohol use disorder.
     Hepatology. 2024;80:1408-1423.
     PubMed     Abstract available
     
     
     
195. MAREK GW, Malhi H
     MetALD: Does it require a different therapeutic option?
     Hepatology. 2024;80:1424-1440.
     PubMed     Abstract available
     
     
     
196. NARAYANAN P, Wu T, Shah VH, Curtis BL, et al
     Insights into ALD and AUD diagnosis and prognosis: Exploring AI and multimodal data streams.
     Hepatology. 2024;80:1480-1494.
     PubMed     Abstract available
     
     
     
197. RAYA TONETTI F, Eguileor A, Mrdjen M, Pathak V, et al
     Gut-liver axis: Recent concepts in pathophysiology in alcohol-associated liver disease.
     Hepatology. 2024;80:1342-1371.
     PubMed     Abstract available
     
     
     
198. ABERG F, Jiang ZG, Cortez-Pinto H, Mannisto V, et al
     Alcohol-associated liver disease-Global epidemiology.
     Hepatology. 2024;80:1307-1322.
     PubMed     Abstract available
     
     
     
199. FU Y, Maccioni L, Wang XW, Greten TF, et al
     Alcohol-associated liver cancer.
     Hepatology. 2024;80:1462-1479.
     PubMed     Abstract available
     
     
     
200. ISRAELSEN M, Rungratanawanich W, Thiele M, Liangpunsakul S, et al
     Non-invasive tests for alcohol-associated liver disease.
     Hepatology. 2024;80:1390-1407.
     PubMed     Abstract available
     
     
     November 2024
201. VERCHER E, Covo-Vergara A, Conde E, Hernandez-Rueda M, et al
     Human T cells engineered with an HLA-A2-restricted murine T-cell receptor targeting Glypican 3 effectively control human hepatocellular carcinoma in mice.
     Hepatology. 2024 Nov 26. doi: 10.1097/HEP.0000000000001175.
     PubMed     Abstract available
     
     
     
202. HAN J, Shan D
     Letter to the Editor: Refining the role of HAF in hepatocellular carcinoma.
     Hepatology. 2024 Nov 21. doi: 10.1097/HEP.0000000000001171.
     PubMed    
     
     
     
203. SCHEINER B, Kang B, Balcar L, Radu IP, et al
     Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy.
     Hepatology. 2024 Nov 21. doi: 10.1097/HEP.0000000000001163.
     PubMed     Abstract available
     
     
     
204. SUMMERS SA, Koh MY
     Reply: Refining the role of HAF in hepatocellular carcinoma.
     Hepatology. 2024 Nov 21. doi: 10.1097/HEP.0000000000001173.
     PubMed    
     
     
     
205. WONG YJ, Teng M, Sim A, Abraldes JG, et al
     Reply: Quality indicators and the safety profile of endoscopic intervention in patients with bleeding esophageal varices.
     Hepatology. 2024 Nov 12. doi: 10.1097/HEP.0000000000001155.
     PubMed    
     
     
     
206. LEVY C, Bowlus CL
     Primary Biliary Cholangitis: personalizing second-line therapies.
     Hepatology. 2024 Nov 12. doi: 10.1097/HEP.0000000000001166.
     PubMed     Abstract available
     
     
     
207. JOHN BV, Bastaich D, Dahman B
     Reply: Association of hepatitis delta virus infection and hepatocellular carcinoma, hepatic decompensation, all-cause and liver-related death in a national cohort.
     Hepatology. 2024 Nov 11. doi: 10.1097/HEP.0000000000001162.
     PubMed    
     
     
     
208. KRIGE JE, Jonas EG, Bernon MM
     Letter to the editor: Quality indicators and the safety profile of endoscopic intervention in patients with bleeding esophageal varices.
     Hepatology. 2024 Nov 11. doi: 10.1097/HEP.0000000000001153.
     PubMed    
     
     
     
209. HE Z, Wang C, Tian H
     Letter to the editor : Association of hepatitis delta virus infection and hepatocellular carcinoma, hepatic decompensation, all-cause and liver-related death in a national cohort.
     Hepatology. 2024 Nov 11. doi: 10.1097/HEP.0000000000001159.
     PubMed    
     
     
     
210. BRUNO BJ, Weavil JC, Ogle J, Chidambaram N, et al
     Oral LPCN 1148 improves sarcopenia and hepatic encephalopathy in male patients with cirrhosis: A randomized, placebo-controlled phase 2 trial.
     Hepatology. 2024 Nov 8. doi: 10.1097/HEP.0000000000001146.
     PubMed     Abstract available
     
     
     
211. LI S, Wu Z
     Letter to the Editor: Enhancing automated speech analysis for hepatic encephalopathy detection.
     Hepatology. 2024 Nov 7. doi: 10.1097/HEP.0000000000001150.
     PubMed    
     
     
     
212. LIAO TL, Chen DY, Hsieh SL, Yang YY, et al
     Platelet-derived mitochondria regulate lipid metabolism in nonalcoholic steatohepatitis via extracellular vesicles.
     Hepatology. 2024 Nov 7. doi: 10.1097/HEP.0000000000001149.
     PubMed     Abstract available
     
     
     
213. ALVARADO-TAPIAS E, Brujats A, Puente A, Ardevol A, et al
     Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with severe portal hypertension and suboptimal response to beta-blockers: A double-blind, placebo-controlled, randomized-trial.
     Hepatology. 2024 Nov 7. doi: 10.1097/HEP.0000000000001148.
     PubMed     Abstract available
     
     
     
214. BLOOM PP, Lok AS
     Reply: Enhancing automated speech analysis for hepatic encephalopathy detection.
     Hepatology. 2024 Nov 7. doi: 10.1097/HEP.0000000000001151.
     PubMed    
     
     
     
215. CHARU V, Liang JW, Mannalithara A, Kwong A, et al
     Benchmarking clinical risk prediction algorithms with ensemble machine learning for the noninvasive diagnosis of liver fibrosis in NAFLD.
     Hepatology. 2024;80:1184-1195.
     PubMed     Abstract available
     
     
     
216. CHALASANI N, Vilar-Gomez E, Loomba R, Yates KP, et al
     PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic dysfunction-associated steatotic liver disease.
     Hepatology. 2024;80:1212-1226.
     PubMed     Abstract available
     
     
     
217. STONEBRAKER JR, Pace RG, Gallins PJ, Dang H, et al
     Genetic variation in severe cystic fibrosis liver disease is associated with novel mechanisms for disease pathogenesis.
     Hepatology. 2024;80:1012-1025.
     PubMed     Abstract available
     
     
     
218. GE J, Sun S, Owens J, Galvez V, et al
     Development of a liver disease-specific large language model chat interface using retrieval-augmented generation.
     Hepatology. 2024;80:1158-1168.
     PubMed     Abstract available
     
     
     
219. ZHANG L, Jiao K, Liu Y, Xu G, et al
     UBXN9 inhibits the RNA exosome function to promote T cell control of liver tumorigenesis.
     Hepatology. 2024;80:1041-1057.
     PubMed     Abstract available
     
     
     
220. GAO W, Zhang L, Li Z, Wu T, et al
     Nuclear Acly protects the liver from ischemia-reperfusion injury.
     Hepatology. 2024;80:1087-1103.
     PubMed     Abstract available
     
     
     
221. 
     Erratum: NK-cell-elicited gasdermin-D-dependent hepatocyte pyroptosis induces neutrophil extracellular traps that facilitates HBV-related acute-on-chronic liver failure.
     Hepatology. 2024;80:E92.
     PubMed    
     
     
     
222. 
     Erratum: Basolateral CD147 induces hepatocyte polarity loss by E-cadherin ubiquitination and degradation in hepatocellular carcinoma progress.
     Hepatology. 2024;80:E91.
     PubMed    
     
     
     
223. 
     Erratum: Diagnosis, Evaluation, and Management of Ascites and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.
     Hepatology. 2024;80:E89.
     PubMed    
     
     
     
224. NARAYANAN P
     PAR for the liver course: Preserving platelet function mitigates outcomes in cirrhosis.
     Hepatology. 2024;80:991-992.
     PubMed    
     
     
     October 2024
225. FAN G, Tao C, Li L, Xie T, et al
     The co-location of MARCO+ tumor-associated macrophages and CTSE+ tumor cells determined the poor prognosis in intrahepatic cholangiocarcinoma.
     Hepatology. 2024 Oct 29. doi: 10.1097/HEP.0000000000001138.
     PubMed     Abstract available
     
     
     
226. VONADA A, Grompe M
     In vivo selection of hepatocytes.
     Hepatology. 2024 Oct 29. doi: 10.1097/HEP.0000000000001143.
     PubMed     Abstract available
     
     
     
227. CIRIA R, Ivanics T, Aliseda D, Claasen M, et al
     Liver transplantation for primary and secondary liver tumours. patient-level meta-analyses compared to unos conventional indications.
     Hepatology. 2024 Oct 28. doi: 10.1097/HEP.0000000000001129.
     PubMed     Abstract available
     
     
     
228. KIM JW, Tung HC, Ke M, Xu P, et al
     The de-sulfinylation enzyme sulfiredoxin-1 attenuates hepatic stellate cell activation and liver fibrosis by modulating the PTPN12-NLRP3 axis.
     Hepatology. 2024 Oct 24. doi: 10.1097/HEP.0000000000001133.
     PubMed     Abstract available
     
     
     
229. ZHOU K, Wang Z, Guo W, Xie F, et al
     Unraveling bidirectional evolution of unstable mitochondrial DNA mutations in hepatocellular carcinoma at single-cell resolution.
     Hepatology. 2024 Oct 11. doi: 10.1097/HEP.0000000000001113.
     PubMed     Abstract available
     
     
     
230. KEZER CA, Berzigotti A, Fortune BE, Simonetto DA, et al
     Drug treatments to prevent first decompensation in cirrhosis.
     Hepatology. 2024 Oct 8. doi: 10.1097/HEP.0000000000001117.
     PubMed     Abstract available
     
     
     
231. FAR A, Bastani A, Lee A, Gologorskaya O, et al
     Evaluating the positive predictive value of code-based identification of cirrhosis and its complications utilizing GPT-4.
     Hepatology. 2024 Oct 8. doi: 10.1097/HEP.0000000000001115.
     PubMed     Abstract available
     
     
     
232. NAKAGAWA H
     New ubiquitomic subtypes in hepatocellular carcinoma: Insights for future therapeutic approaches.
     Hepatology. 2024 Oct 7. doi: 10.1097/HEP.0000000000001116.
     PubMed    
     
     
     
233. GIRI N, Niewisch MR, Rosenberg PS, Vittal A, et al
     Reply: Accurate predictor for liver disease progression in patients with DC/TBD.
     Hepatology. 2024;80:E61-E62.
     PubMed    
     
     
     
234. ZHAO J, Bi Y
     Letter to the Editor: Accurate predictor for liver disease progression in patients with DC/TBD.
     Hepatology. 2024;80:E60.
     PubMed    
     
     
     
235. EL-SHABRAWI MHF, Elamin A, Kamal NM
     Letter to the Editor: MAFLD versus MASLD criteria debate- Certainly not for children!
     Hepatology. 2024;80:E55-E56.
     PubMed    
     
     
     
236. LA VECCHIA C, Santucci C
     Liver cancer in young adults: Validity of global data sets.
     Hepatology. 2024;80:766-769.
     PubMed    
     
     
     
237. DANPANICHKUL P, Aboona MB, Sukphutanan B, Kongarin S, et al
     Incidence of liver cancer in young adults according to the Global Burden of Disease database 2019.
     Hepatology. 2024;80:828-843.
     PubMed     Abstract available
     
     
     
238. CHEUNG KS, Ng HY, Hui RWH, Lam LK, et al
     Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial.
     Hepatology. 2024;80:916-927.
     PubMed     Abstract available
     
     
     
239. TANG S, Borlak J
     Genomics of human NAFLD: Lack of data reproducibility and high interpatient variability in drug target expression as major causes of drug failures.
     Hepatology. 2024;80:901-915.
     PubMed     Abstract available
     
     
     
240. SU GL, Zhang P, Belancourt PX, Youles B, et al
     Incorporation of quantitative imaging data using artificial intelligence improves risk prediction in veterans with liver disease.
     Hepatology. 2024;80:928-936.
     PubMed     Abstract available
     
     
     
241. PENRICE DD, Jalan-Sakrikar N, Jurk D, Passos JF, et al
     Telomere dysfunction in chronic liver disease: The link from aging.
     Hepatology. 2024;80:951-964.
     PubMed    
     
     
     
242. SAMPLE JW
     Beyond monotherapy: Combining radiotherapy with sintilimab and bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus.
     Hepatology. 2024;80:757-758.
     PubMed    
     
     
     September 2024
243. LIN XT, Luo YD, Mao C, Gong Y, et al
     Integrated ubiquitomics characterization of hepatocellular carcinomas.
     Hepatology. 2024 Sep 30. doi: 10.1097/HEP.0000000000001096.
     PubMed     Abstract available
     
     
     
244. KODAMA T
     Geographical and molecular disparity of HBV integration: Implications for hepatocarcinogenesis and clinical outcomes in HCC.
     Hepatology. 2024 Sep 30. doi: 10.1097/HEP.0000000000001111.
     PubMed    
     
     
     
245. NOUREDDIN M, Truong E, Mayo R, Martinez-Arranz I, et al
     Letter to the Editor: Serum identification of At-Risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF).
     Hepatology. 2024 Sep 26. doi: 10.1097/HEP.0000000000001061.
     PubMed    
     
     
     
246. AJOUAOU Y, Sadler KC
     Uncovering epigenetic heterogeneity in hepatocellular carcinoma.
     Hepatology. 2024 Sep 18. doi: 10.1097/HEP.0000000000001097.
     PubMed    
     
     
     
247. LYU X, Sze KM, Lee JM, Husain A, et al
     Disparity landscapes of viral-induced structural variations in hepatocellular carcinoma: Mechanistic characterization and functional implications.
     Hepatology. 2024 Sep 13. doi: 10.1097/HEP.0000000000001087.
     PubMed     Abstract available
     
     
     
248. BLOOM PP, Fisher CJ, Tedesco N, Kamdar N, et al
     HEAR-MHE study: Automated speech analysis identifies minimal hepatic encephalopathy and may predict future overt hepatic encephalopathy.
     Hepatology. 2024 Sep 12. doi: 10.1097/HEP.0000000000001086.
     PubMed     Abstract available
     
     
     
249. ACUNA-PILARTE K, Reichert EC, Song Green Y, Halberg LM, et al
     HAF prevents hepatocyte apoptosis and progression to MASH and hepatocellular carcinoma through transcriptional regulation of the NF-kappaB pathway.
     Hepatology. 2024 Sep 10. doi: 10.1097/HEP.0000000000001070.
     PubMed     Abstract available
     
     
     
250. JOHN BV, Bastaich D, Amoli MM, Wong RJ, et al
     Association of hepatitis delta virus infection and hepatocellular carcinoma, hepatic decompensation, all-cause and liver-related death in a national cohort.
     Hepatology. 2024 Sep 10. doi: 10.1097/HEP.0000000000001092.
     PubMed     Abstract available
     
     
     
251. YOUNOSSI ZM, Stepanova M, Racila A, Henry L, et al
     Health-Related quality of life (HRQL) assessments in a 52-Week, Double-Blind, randomized, Placebo-Controlled phase 3 study of resmetirom (MGL-3196) in patients with metabolic dysfunction associated steatohepatitis (MASH) and fibrosis.
     Hepatology. 2024 Sep 6. doi: 10.1097/HEP.0000000000001084.
     PubMed     Abstract available
     
     
     
252. WU Y, Li L, Li W, Li N, et al
     Stretch-induced hepatic endothelial mechanocrine promotes hepatocyte proliferation.
     Hepatology. 2024 Sep 6. doi: 10.1097/HEP.0000000000001082.
     PubMed     Abstract available
     
     
     
253. 
     Hepatology Highlights.
     Hepatology. 2024;80:501-502.
     PubMed    
     
     
     
254. VILLANI R, Serviddio G
     Letter to the Editor: Multifactorial steatotic liver disease: A new entity to be included in new international classification of liver steatosis.
     Hepatology. 2024;80:E40-E41.
     PubMed    
     
     
     
255. ALBORAIE M, Fouad Y, Eslam M
     Letter to the Editor: MAFLD versus MASLD-Which is more appropriate from a global perspective?
     Hepatology. 2024;80:E42-E43.
     PubMed    
     
     
     
256. CHUNG SW, Moon HS, Shin H, Han H, et al
     Inhibition of sodium-glucose cotransporter-2 and liver-related complications in individuals with diabetes: a Mendelian randomization and population-based cohort study.
     Hepatology. 2024;80:633-648.
     PubMed     Abstract available
     
     
     
257. TERBAH R, Testro AG, Hoermann R, Majumdar A, et al
     Continuous home terlipressin infusion increases handgrip strength and reduces ascites-A prospective randomized crossover study.
     Hepatology. 2024;80:605-620.
     PubMed     Abstract available
     
     
     
258. WATLING CZ, Wojt A, Florio AA, Butera G, et al
     Fiber and whole grain intakes in relation to liver cancer risk: An analysis in 2 prospective cohorts and systematic review and meta-analysis of prospective studies.
     Hepatology. 2024;80:552-565.
     PubMed     Abstract available
     
     
     
259. LIN P, Yan X, Jing S, Wu Y, et al
     Single-cell and spatially resolved transcriptomics for liver biology.
     Hepatology. 2024;80:698-720.
     PubMed     Abstract available
     
     
     
260. 
     Hepatology Highlights.
     Hepatology. 2024;80:501-502.
     PubMed    
     
     
     August 2024
261. FACCIOLI LA, Sun Y, Animasahun O, Motomura T, et al
     Human induced pluripotent stem cell based hepatic-modeling of lipid metabolism associated TM6SF2 E167K variant.
     Hepatology. 2024 Aug 27. doi: 10.1097/HEP.0000000000001065.
     PubMed     Abstract available
     
     
     
262. LUCAS MR, Pilling LC, Atkins JL, Melzer D, et al
     Incidence of liver complications with hemochromatosis associated HFE p.C282Y homozygosity: The role of central adiposity.
     Hepatology. 2024 Aug 23. doi: 10.1097/HEP.0000000000001056.
     PubMed     Abstract available
     
     
     
263. VAN DER MEER AJ, Sonneveld MJ
     Towards risk-based surveillance for hepatocellular carcinoma after HCV cure?
     Hepatology. 2024 Aug 13. doi: 10.1097/HEP.0000000000001057.
     PubMed    
     
     
     
264. LIM HY, Heo J, Peguero JA, Ryoo BY, et al
     Efficacy and safety of bintrafusp alfa in two phase 1 expansion cohorts with advanced hepatocellular carcinoma.
     Hepatology. 2024 Aug 13. doi: 10.1097/HEP.0000000000001054.
     PubMed     Abstract available
     
     
     
265. BJORNSSON ES, Devarbhavi HC
     Drug induced cholestatic liver diseases.
     Hepatology. 2024 Aug 8. doi: 10.1097/HEP.0000000000001052.
     PubMed     Abstract available
     
     
     
266. SHANG Y, Akbari C, Dodd M, Zhang X, et al
     Association between longitudinal biomarkers and major adverse liver outcomes in patients with non-cirrhotic metabolic dysfunction-associated steatotic liver disease.
     Hepatology. 2024 Aug 7. doi: 10.1097/HEP.0000000000001045.
     PubMed     Abstract available
     
     
     
267. NAULT JC, Iavarone M
     Management of patients with advanced hepatocellular carcinoma receiving atezolizumab/bevacizumab: Take care of cirrhosis!
     Hepatology. 2024 Aug 5. doi: 10.1097/HEP.0000000000001047.
     PubMed    
     
     
     
268. 
     Hepatology Highlights.
     Hepatology. 2024;80:255-256.
     PubMed    
     
     
     
269. GARCIA-TSAO G, Kaplan DE
     Reply: Endoscopy for potential variceal bleeding within 12 hours-Not so fast!
     Hepatology. 2024;80:E36.
     PubMed    
     
     
     
270. RAMAN KP, Patch D
     Tranexamic acid in variceal bleeding revisited.
     Hepatology. 2024;80:257-259.
     PubMed    
     
     
     
271. JEPSEN P, West J, Kann AE, Kraglund F, et al
     Risk of alcohol-associated liver disease in the offspring of parents with alcohol-associated liver disease: A nationwide cohort study.
     Hepatology. 2024;80:418-427.
     PubMed     Abstract available
     
     
     
272. WANG Q, Bu Q, Pan B, Yin Y, et al
     Letter to the Editor: Scavenger receptor a is a major homeostatic regulator that restrains drug-induced liver injury.
     Hepatology. 2024;80:E24-E25.
     PubMed    
     
     
     
273. YANG D, Tian T, Li X, Zhang B, et al
     ZNT1 and Zn 2+ control TLR4 and PD-L1 endocytosis in macrophages to improve chemotherapy efficacy against liver tumor.
     Hepatology. 2024;80:312-329.
     PubMed     Abstract available
     
     
     
274. HLADY RA, Robertson KD
     Epigenetic memory of environmental exposures as a mediator of liver disease.
     Hepatology. 2024;80:451-464.
     PubMed     Abstract available
     
     
     July 2024
275. LIM N, Devuni D, German M, Guy J, et al
     The rise of multidisciplinary clinics in hepatology: A practical, how-to-guide, and review of the literature.
     Hepatology. 2024 Jul 30. doi: 10.1097/HEP.0000000000001036.
     PubMed     Abstract available
     
     
     
276. WANG X, Liu Y, Zhang S, Zhang J, et al
     Genomic and transcriptomic analyses of chemical hepatocarcinogenesis aggravated by oncoprotein loss.
     Hepatology. 2024 Jul 30. doi: 10.1097/HEP.0000000000001037.
     PubMed     Abstract available
     
     
     
277. WANG M, Chiou SH, Ganger D, Ruck J, et al
     Liver transplantation provides survival benefit at all levels of frailty: From the Multicenter Functional Assessment in Liver Transplantation Study.
     Hepatology. 2024 Jul 24. doi: 10.1097/HEP.0000000000001030.
     PubMed     Abstract available
     
     
     
278. JEONG JM, Choi SE, Shim YR, Kim HH, et al
     CX3CR1+ macrophages interact with hepatic stellate cells to promote hepatocellular carcinoma through CD8+ T cell suppression.
     Hepatology. 2024 Jul 19. doi: 10.1097/HEP.0000000000001021.
     PubMed     Abstract available
     
     
     
279. CELSA C, Cabibbo G, Fulgenzi CAM, Battaglia S, et al
     Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment.
     Hepatology. 2024 Jul 19. doi: 10.1097/HEP.0000000000001026.
     PubMed     Abstract available
     
     
     
280. 
     Diagnosis and Management of Hepatocellular Carcinoma.
     Hepatology. 2024 Jul 17. doi: 10.1097/HEP.0000000000001010.
     PubMed    
     
     
     
281. ZHANG L, Xie P, Li M, Zhang X, et al
     Hepatic GDP-fucose transporter SLC35C1 attenuates cholestatic liver injury and inflammation by inducing CEACAM1 N153 fucosylation.
     Hepatology. 2024 Jul 10. doi: 10.1097/HEP.0000000000001003.
     PubMed     Abstract available
     
     
     
282. HUANG Y, Yu F, Ding Y, Zhang H, et al
     Hepatic IL22RA1 deficiency promotes hepatic steatosis by modulating oxysterol in the liver.
     Hepatology. 2024 Jul 10. doi: 10.1097/HEP.0000000000000998.
     PubMed     Abstract available
     
     
     
283. HOOVER JM
     Letter to the Editor: Utilization of beta blockers in patients with portal hypertension and peripheral artery disease.
     Hepatology. 2024 Jul 8. doi: 10.1097/HEP.0000000000001008.
     PubMed    
     
     
     
284. KENT D, Ng SS, Syanda AM, Khoshkenar P, et al
     Reduction of Z alpha-1 antitrypsin polymers in human iPSC-hepatocytes and mice by LRRK2 inhibitors.
     Hepatology. 2024 Jul 2. doi: 10.1097/HEP.0000000000000969.
     PubMed     Abstract available
     
     
     
285. 
     Erratum: A prognostic strategy based on stage of cirrhosis and HVPG to improve risk stratification after variceal bleeding.
     Hepatology. 2024;80:E23.
     PubMed    
     
     
     
286. 
     Hepatology Highlights.
     Hepatology. 2024;80:1-2.
     PubMed    
     
     
     
287. LAINE L, Barkun AN, Leontiadis GI
     Letter to the Editor: Endoscopy for potential variceal bleeding within 12 hours-Not so fast!
     Hepatology. 2024;80:E15-E16.
     PubMed    
     
     
     
288. KRAWCZYK M, Lammert F
     Letter to the Editor: NAFLD vs. MASLD-There ain't no such thing as a free lunch.
     Hepatology. 2024;80:E11-E12.
     PubMed    
     
     
     
289. RINELLA ME, Lazarus JV, Newsome PN
     Reply: NAFLD vs. MASLD-There ain't no such thing as a free lunch.
     Hepatology. 2024;80:E13-E14.
     PubMed    
     
     
     
290. MA J, Liangpunsakul S
     Solving the puzzle of fibrosis resolution in alcohol-associated liver disease: An insight from KDM5 demethylases and LXR activation.
     Hepatology. 2024;80:14-17.
     PubMed    
     
     
     
291. DAVENPORT M
     Serum matrix metalloproteinase-7 (MMP-7): As good as it gets?
     Hepatology. 2024;80:18-19.
     PubMed    
     
     
     
292. WOLTERS F, Oude Elferink RPJ, Beuers U
     PPARalpha, PPARdelta, or both-that is the question!
     Hepatology. 2024;80:8-10.
     PubMed    
     
     
     
293. KOSHIOL J, Krawczyk M
     enHanCCing knowledge of genetic factors in primary liver tumor.
     Hepatology. 2024;80:11-13.
     PubMed    
     
     
     
294. NEIL DAH, Smith ML, Minervini M, Demetris AJ, et al
     Reply: Additional viewpoints from transplant surgeons on Banff consensus recommendations for the assessment of steatotic donor livers.
     Hepatology. 2024;80:E6-E7.
     PubMed    
     
     
     
295. CAO H, Gu J
     Letter to the Editor: Additional viewpoints from transplant surgeons on Banff consensus recommendations for the assessment of steatotic donor livers.
     Hepatology. 2024;80:E4-E5.
     PubMed    
     
     
     
296. ABERG F, Asteljoki J, Mannisto V, Luukkonen PK, et al
     Combined use of the CLivD score and FIB-4 for prediction of liver-related outcomes in the population.
     Hepatology. 2024;80:163-172.
     PubMed     Abstract available
     
     
     
297. FLORIS A, Chandla S, Lim Y, Barbier-Torres L, et al
     Sumoylation of methionine adenosyltransferase alpha 1 promotes mitochondrial dysfunction in alcohol-associated liver disease.
     Hepatology. 2024;80:102-118.
     PubMed     Abstract available
     
     
     
298. LOPEZ-PASCUAL A
     Navigating liver disease complexity: Innovations in in vitro modeling and precision medicine.
     Hepatology. 2024;80:20-23.
     PubMed    
     
     
     
299. SCHONFELD M, O'Neil M, Weinman SA, Tikhanovich I, et al
     Alcohol-induced epigenetic changes prevent fibrosis resolution after alcohol cessation in miceresolution.
     Hepatology. 2024;80:119-135.
     PubMed     Abstract available
     
     
     
300. TONG Y, Wang F, Li S, Guo W, et al
     Histone methyltransferase KMT5C drives liver cancer progression and directs therapeutic response to PARP inhibitors.
     Hepatology. 2024;80:38-54.
     PubMed     Abstract available
     
     
     
301. SINGAL AK, Shah VH, Malhi H
     Emerging targets for therapy in ALD: Lessons from NASH.
     Hepatology. 2024;80:223-237.
     PubMed     Abstract available
     
     
     
302. 
     Erratum: c-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair.
     Hepatology. 2024;80:E21.
     PubMed    
     
     
     
303. PREMKUMAR M, Karvellas CJ, Kulkarni AV, Bhujade H, et al
     Role of Point-of-Care ultrasound (POCUS) in clinical hepatology.
     Hepatology. 2024 Jul 1. doi: 10.1097/HEP.0000000000000990.
     PubMed     Abstract available
     
     
     June 2024
304. GAO D, Ping Yam JW
     Reversal of lipid metabolism as a therapeutic approach for hepatocellular carcinoma.
     Hepatology. 2024 Jun 27. doi: 10.1097/HEP.0000000000001000.
     PubMed    
     
     
     
305. PREMKUMAR M, Kulkarni A, Izzy M
     'Regarding Evaluation of terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury using point-of-care echocardiography'.
     Hepatology. 2024 Jun 26. doi: 10.1097/HEP.0000000000000988.
     PubMed    
     
     
     
306. LUO X, Yu J
     Regarding terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury.
     Hepatology. 2024 Jun 25. doi: 10.1097/HEP.0000000000000984.
     PubMed    
     
     
     
307. RATZIU V, Yilmaz Y, Lazas D, Friedman SL, et al
     Aramchol improves hepatic fibrosis in MASH: Results of multimodality assessment using both conventional and digital pathology.
     Hepatology. 2024 Jun 25. doi: 10.1097/HEP.0000000000000980.
     PubMed     Abstract available
     
     
     
308. KANG K, Wu Y
     Letter to the Editor: Regarding the use of decision curve analysis in predicting long-term complications of liver cirrhosis.
     Hepatology. 2024 Jun 21. doi: 10.1097/HEP.0000000000000945.
     PubMed    
     
     
     
309. LI J, Ma X, Xuan Q, Li Q, et al
     Modulation of monocyte activity by hepatocellular MicroRNA delivery via hepatitis B virus surface antigen particles: Implications for pathobiology of chronic hepatitis B.
     Hepatology. 2024 Jun 20. doi: 10.1097/HEP.0000000000000972.
     PubMed     Abstract available
     
     
     
310. YANG M, Song X, Zhang F, Li M, et al
     Spatial proteomic landscape of primary and relapsed hepatocellular carcinoma reveals immune escape characteristics in early relapse.
     Hepatology. 2024 Jun 20. doi: 10.1097/HEP.0000000000000979.
     PubMed     Abstract available
     
     
     
311. BERENGUER J, Bellon JM, Banares R, Gonzalez-Garcia J, et al
     Reply: Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis.
     Hepatology. 2024 Jun 20. doi: 10.1097/HEP.0000000000000977.
     PubMed    
     
     
     
312. LIU Q, Zhang X, Qi J, Tian X, et al
     Comprehensive profiling of lipid metabolic reprogramming expands precision medicine for hepatocellular carcinoma.
     Hepatology. 2024 Jun 19. doi: 10.1097/HEP.0000000000000962.
     PubMed     Abstract available
     
     
     
313. SIMONETTO DA, Winder GS, Connor AA, Terrault NA, et al
     Liver transplantation for Alcohol-associated liver disease.
     Hepatology. 2024 Jun 18. doi: 10.1097/HEP.0000000000000978.
     PubMed     Abstract available
     
     
     
314. 
     Process Measures to Improve Outcomes During Peri-Procedure Management of Coagulopathy in Cirrhosis.
     Hepatology. 2024 Jun 17. doi: 10.1097/HEP.0000000000000964.
     PubMed    
     
     
     
315. HUANG L, Zou L
     Letter to the Editor: Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis.
     Hepatology. 2024 Jun 17. doi: 10.1097/HEP.0000000000000974.
     PubMed    
     
     
     
316. 
     Erratum: Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3.
     Hepatology. 2024;79:E171-E172.
     PubMed    
     
     
     
317. 
     Hepatology Highlights.
     Hepatology. 2024;79:1239-1240.
     PubMed    
     
     
     
318. LI Z, Zhang Y, Li Y, Lan J, et al
     Letter to the Editor: Statins as potential confounding factors to investigate the association between the use of GLP-1 receptor agonists and risk of HCC.
     Hepatology. 2024;79:E169-E170.
     PubMed    
     
     
     
319. LOMBARDI R, Dalbeni A, Mantovani A, Ravaioli F, et al
     Reply: AGILE 3+ score, enhancing the diagnostic accuracy of advanced fibrosis in patients with nonalcoholic fatty liver disease.
     Hepatology. 2024;79:E155-E156.
     PubMed    
     
     
     
320. CALZADILLA-BERTOT L, Jeffrey AW, Jeffrey GP
     Letter to the Editor: AGILE 3+ score, enhancing the diagnostic accuracy of advanced fibrosis in patients with nonalcoholic fatty liver disease.
     Hepatology. 2024;79:E153-E154.
     PubMed    
     
     
     
321. YEH JG, Newsome PN
     Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study.
     Hepatology. 2024;79:1255-1257.
     PubMed    
     
     
     
322. HANSEN BE, Vandriel SM, Vig P, Garner W, et al
     Event-free survival of maralixibat-treated patients with Alagille syndrome compared to a real-world cohort from GALA.
     Hepatology. 2024;79:1279-1292.
     PubMed     Abstract available
     
     
     
323. ABDELMALEK MF, Rinella ME
     Steatotic liver disease, a useful construct in primary care that doesn't upset the apple cart.
     Hepatology. 2024;79:1252-1254.
     PubMed    
     
     
     
324. ENGSTROM A, Wintzell V, Melbye M, Svanstrom H, et al
     Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study.
     Hepatology. 2024;79:1401-1411.
     PubMed     Abstract available
     
     
     
325. ZHAO G, Ma Q, Yang H, Jiang H, et al
     Base editing of the mutated TERT promoter inhibits liver tumor growth.
     Hepatology. 2024;79:1310-1323.
     PubMed     Abstract available
     
     
     
326. SCHMIDT KA, Simonetto DA
     The telomere tango: Liver disease in the genomic spotlight.
     Hepatology. 2024;79:1249-1251.
     PubMed    
     
     
     
327. SIDALI S, Borie R, Sicre de Fontbrune F, El Husseini K, et al
     Liver disease in germline mutations of telomere-related genes: Prevalence, clinical, radiological, pathological features, outcome, and risk factors.
     Hepatology. 2024;79:1365-1380.
     PubMed     Abstract available
     
     
     
328. UMBAUGH DS, Nguyen NT, Curry SC, Rule JA, et al
     The chemokine CXCL14 is a novel early prognostic biomarker for poor outcome in acetaminophen-induced acute liver failure.
     Hepatology. 2024;79:1352-1364.
     PubMed     Abstract available
     
     
     
329. WANG A, Blackford AL, Behling C, Wilson LA, et al
     Development of Fibro-PeN, a clinical prediction model for moderate-to-severe fibrosis in children with nonalcoholic fatty liver disease.
     Hepatology. 2024;79:1381-1392.
     PubMed     Abstract available
     
     
     
330. JIN Y, Shou Y, Lei Q, Du C, et al
     An entropy weight method to integrate big omics and mechanistically evaluate DILI.
     Hepatology. 2024;79:1264-1278.
     PubMed     Abstract available
     
     
     
331. AFONSO MB, Marques V, van Mil SWC, Rodrigues CMP, et al
     Human liver organoids: From generation to applications.
     Hepatology. 2024;79:1432-1451.
     PubMed     Abstract available
     
     
     May 2024
332. MANTOVANI S, Mondelli MU
     Platelets harness innate immunity to promote dissemination of hepatocellular carcinoma.
     Hepatology. 2024 May 29. doi: 10.1097/HEP.0000000000000946.
     PubMed    
     
     
     
333. GUO C, Liu Z, Zhang T
     Reply: Regarding the use of decision curve analysis in predicting long-term complications of liver cirrhosis.
     Hepatology. 2024 May 29. doi: 10.1097/HEP.0000000000000947.
     PubMed    
     
     
     
334. MUSSO G, Pinach S, Mariano F, Saba F, et al
     Effect of phospholipid curcumin Meriva(R) on liver histology and kidney disease in nonalcoholic steatohepatitis a randomized, double-blind, placebo-controlled trial.
     Hepatology. 2024 May 28. doi: 10.1097/HEP.0000000000000937.
     PubMed     Abstract available
     
     
     
335. LI B, Yang Y, Shi J, Li Y, et al
     Letter to the Editor: Molecular classification based on multi-omics facilitates prognostic stratification and personalized treatment in hepatocellular carcinoma.
     Hepatology. 2024 May 28. doi: 10.1097/HEP.0000000000000944.
     PubMed    
     
     
     
336. MOORE MP, Wang X, Kennelly JP, Shi H, et al
     Low MBOAT7 expression, a genetic risk for MASH, promotes a pro-fibrotic pathway involving hepatocyte TAZ upregulation.
     Hepatology. 2024 May 22. doi: 10.1097/HEP.0000000000000933.
     PubMed     Abstract available
     
     
     
337. KANWAL F, Neuschwander-Tetri BA, Loomba R, Rinella ME, et al
     Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease.
     Hepatology. 2024;79:1212-1219.
     PubMed     Abstract available
     
     
     
338. NABI O, Lapidus N, Boursier J, de Ledinghen V, et al
     Reply: Concerns regarding the use of Fatty Liver Index in studies of lean NAFLD.
     Hepatology. 2024;79:E130-E131.
     PubMed    
     
     
     
339. ZAHRAWI FM, Mehal WZ
     Letter to the Editor: Concerns regarding the use of fatty liver index in studies of lean NAFLD.
     Hepatology. 2024;79:E129.
     PubMed    
     
     
     
340. STOCKDALE AJ, Degasperi E
     HDV RNA and liver disease progression: What do we know?
     Hepatology. 2024;79:983-985.
     PubMed    
     
     
     
341. DESERT R, Foucher F, Guillout M, Nieto N, et al
     Reply: Intratumor fibrotic HCC, a subtype matching the Hoshida S1 subclass?
     Hepatology. 2024;79:E141-E143.
     PubMed    
     
     
     
342. WANG TC, Xiao YD, Zhou P
     Letter to the Editor: Intratumor fibrotic HCC, a subtype matching the Hoshida S1 subclass?
     Hepatology. 2024;79:E140.
     PubMed    
     
     
     
343. LIU H, Li H, Wang DX, Li T, et al
     Letter to the Editor: Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis.
     Hepatology. 2024;79:E144-E145.
     PubMed    
     
     
     
344. DALBENI A, Mantovani A, Lombardi R, Ravaioli F, et al
     Reply: Diagnostic accuracy of AGILE3+ score for advanced fibrosis in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
     Hepatology. 2024;79:E146-E147.
     PubMed    
     
     
     
345. KIRK FT, Munk DE, Swenson ES, Quicquaro AM, et al
     Effects of trientine and penicillamine on intestinal copper uptake: A mechanistic 64 Cu PET/CT study in healthy humans.
     Hepatology. 2024;79:1065-1074.
     PubMed     Abstract available
     
     
     
346. SQUIRES JE, Horslen SP
     Incorporation of genetic testing into the diagnostic algorithms of PALF: The time is now.
     Hepatology. 2024;79:970-972.
     PubMed    
     
     
     
347. DALBENI A, Lombardi R, Henrique M, Zoncape M, et al
     Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis.
     Hepatology. 2024;79:1107-1116.
     PubMed     Abstract available
     
     
     
348. LENZ D, Schlieben LD, Shimura M, Bianzano A, et al
     Genetic landscape of pediatric acute liver failure of indeterminate origin.
     Hepatology. 2024;79:1075-1087.
     PubMed     Abstract available
     
     
     
349. AJMERA V, Tesfai K, Sandoval E, Lopez S, et al
     Validation of AGA clinical care pathway and AASLD practice guidance for nonalcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes.
     Hepatology. 2024;79:1098-1106.
     PubMed     Abstract available
     
     
     
350. TONIUTTO P, Shalaby S, Mameli L, Morisco F, et al
     Role of sex in liver tumor occurrence and clinical outcomes: A comprehensive review.
     Hepatology. 2024;79:1141-1157.
     PubMed     Abstract available
     
     
     
351. SANTOS AA, Delgado TC, Marques V, Ramirez-Moncayo C, et al
     Spatial metabolomics and its application in the liver.
     Hepatology. 2024;79:1158-1179.
     PubMed     Abstract available
     
     
     
352. 
     Erratum: Overexpressed-eIF3I interacted and activated oncogenic Akt1 is a theranostic target in human hepatocellular carcinoma.
     Hepatology. 2024;79:E150-E151.
     PubMed    
     
     
     April 2024
353. KUMAR M, Venishetty S
     Reply: Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis - A randomized controlled trial.
     Hepatology. 2024 Apr 30. doi: 10.1097/HEP.0000000000000916.
     PubMed    
     
     
     
354. ELKRIEF L, Denecheau-Girard C, Magaz M, Praktiknjo M, et al
     Abdominal surgery in patients with chronic noncirrhotic extra hepatic portal vein obstruction: A multicenter retrospective study.
     Hepatology. 2024 Apr 29. doi: 10.1097/HEP.0000000000000901.
     PubMed     Abstract available
     
     
     
355. LI X, Zhang Y, Li S, Shi J, et al
     Macrophage hitchhiking for systematic suppression in postablative multifocal hepatocellular carcinoma.
     Hepatology. 2024 Apr 29. doi: 10.1097/HEP.0000000000000903.
     PubMed     Abstract available
     
     
     
356. CHOPRA SY, Rawat VL, Ingle MA, Lad SG, et al
     Letter to Editor: Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis - a randomized controlled trial.
     Hepatology. 2024 Apr 29. doi: 10.1097/HEP.0000000000000915.
     PubMed    
     
     
     
357. OCHOA-ALLEMANT P, Serper M, Wang RX, Tang H, et al
     Waitlisting and liver transplantation for MetALD in the United States: An analysis of the UNOS national registry.
     Hepatology. 2024 Apr 29. doi: 10.1097/HEP.0000000000000914.
     PubMed     Abstract available
     
     
     
358. HITOMI Y, Ueno K, Aiba Y, Nishida N, et al
     A genome-wide association study identified PTPN2 as a population-specific susceptibility gene locus for primary biliary cholangitis.
     Hepatology. 2024 Apr 23. doi: 10.1097/HEP.0000000000000894.
     PubMed     Abstract available
     
     
     
359. LEE YT, Tseng HR, Yang JD
     Clonal hematopoiesis of indeterminate potential and risk of hepatocellular carcinoma: New kids on the block.
     Hepatology. 2024 Apr 19. doi: 10.1097/HEP.0000000000000898.
     PubMed    
     
     
     
360. GUO C, Liu Z, Fan H, Wang H, et al
     Machine learning-based plasma metabolomic profiles for predicting long-term complications of cirrhosis.
     Hepatology. 2024 Apr 17. doi: 10.1097/HEP.0000000000000879.
     PubMed     Abstract available
     
     
     
361. HAZARI Y, Chevet E, Bailly-Maitre B, Hetz C, et al
     ER stress signaling at the interphase between MASH and hepatocellular carcinoma.
     Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000893.
     PubMed     Abstract available
     
     
     
362. PRZYBYSZEWSKI EM, Bhan I, Yarze JC
     Letter to the Editor: On the use of non-selective beta blockers in cirrhosis.
     Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000888.
     PubMed    
     
     
     
363. GARCIA-TSAO G, Kaplan DE
     Reply: On the use of non-selective beta blockers in cirrhosis.
     Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000889.
     PubMed    
     
     
     
364. VOLK ML
     Innovations in Healthcare Delivery for Patients with Cirrhosis.
     Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000892.
     PubMed    
     
     
     
365. MOGHE A, McGuire BM, Levy C
     Acute hepatic porphyrias - a guide for Hepatologists.
     Hepatology. 2024 Apr 12. doi: 10.1097/HEP.0000000000000880.
     PubMed     Abstract available
     
     
     
366. SUN C, Zhou C, Daneshvar K, Ben Saad A, et al
     Conserved long noncoding RNA TILAM promotes liver fibrosis through interaction with PML in hepatic stellate cells.
     Hepatology. 2024 Apr 2. doi: 10.1097/HEP.0000000000000822.
     PubMed     Abstract available
     
     
     
367. LI J, Allen AM, Yin M
     Reply: Comparing quantitative MRI technologies in steatotic liver disease.
     Hepatology. 2024;79:E121-E122.
     PubMed    
     
     
     
368. ALKHOURI N, Harisinghani M
     Letter to the Editor: Comparing quantitative MRI technologies in steatotic liver disease.
     Hepatology. 2024;79:E119-E120.
     PubMed    
     
     
     
369. FRANSES JW, Duda DG
     Scirrhous HCC: Another 'omic thread in the HCC tapestry.
     Hepatology. 2024;79:747-748.
     PubMed    
     
     
     
370. VOLKERT I, Fromme M, Schneider C, Candels L, et al
     Impact of PNPLA3 I148M on alpha-1 antitrypsin deficiency-dependent liver disease progression.
     Hepatology. 2024;79:898-911.
     PubMed     Abstract available
     
     
     
371. LADD AD, Duarte S, Sahin I, Zarrinpar A, et al
     Mechanisms of drug resistance in HCC.
     Hepatology. 2024;79:926-940.
     PubMed     Abstract available
     
     
     
372. 
     Erratum: Identification and characterization of a hepatic IL-13-producing ILC3-like population potentially involved in liver fibrosis.
     Hepatology. 2024;79:E128.
     PubMed    
     
     
     
373. 
     Erratum: HCC EV ECG score: An extracellular vesicle-based protein assay for detection of early-stage hepatocellular carcinoma.
     Hepatology. 2024;79:E127.
     PubMed    
     
     
     
374. 
     April 2024 Hepatology Highlights.
     Hepatology. 2024;79:745-746.
     PubMed    
     
     
     
375. TAFALENG EN, Li J, Wang Y, Hidvegi T, et al
     Variants in autophagy genes MTMR12 and FAM134A are putative modifiers of the hepatic phenotype in alpha1-antitrypsin deficiency.
     Hepatology. 2024 Apr 1. doi: 10.1097/HEP.0000000000000865.
     PubMed     Abstract available
     
     
     
376. TAPPER EB, Warner MA, Shah RP, Emamaullee J, et al
     Management of coagulopathy among patients with cirrhosis undergoing upper endoscopy and paracentesis: Persistent gaps and areas of consensus in a multispecialty Delphi.
     Hepatology. 2024 Apr 1. doi: 10.1097/HEP.0000000000000856.
     PubMed     Abstract available
     
     
     March 2024
377. 
     Erratum: AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis.
     Hepatology. 2024 Mar 29. doi: 10.1097/HEP.0000000000000857.
     PubMed    
     
     
     
378. DENG T, Chen G
     Single-cell based molecular classification in systematic treatment of hepatocellular carcinoma: From in silico to bedside.
     Hepatology. 2024 Mar 28. doi: 10.1097/HEP.0000000000000874.
     PubMed    
     
     
     
379. CRUZ C, Prado CM, Gillis C, Martindale R, et al
     Nutritional aspects of prehabilitation in adults with cirrhosis awaiting liver transplant.
     Hepatology. 2024 Mar 28. doi: 10.1097/HEP.0000000000000818.
     PubMed     Abstract available
     
     
     
380. FENG X, Feng B, Zhou J, Yang J, et al
     Mesenchymal stem cells alleviate mouse liver fibrosis by inhibiting pathogenic function of intrahepatic B cells.
     Hepatology. 2024 Mar 28. doi: 10.1097/HEP.0000000000000831.
     PubMed     Abstract available
     
     
     
381. GOLDBERG DT, Yaskolka Meir A, Tsaban G, Rinott E, et al
     Novel proteomic signatures may indicate MRI-assessed intrahepatic fat state and changes; the DIRECT PLUS clinical trial.
     Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000867.
     PubMed     Abstract available
     
     
     
382. ZHAO Q, Chen DP, Chen HD, Wang YZ, et al
     NK-cell-elicited gasdermin-D-dependent hepatocyte pyroptosis induces neutrophil extracellular traps that facilitates HBV-related acute-on-chronic liver failure.
     Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000868.
     PubMed     Abstract available
     
     
     
383. CHEN Y, Deng X, Li Y, Han Y, et al
     Comprehensive molecular classification predicted microenvironment profiles and therapy response for hepatocellular carcinoma.
     Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000869.
     PubMed     Abstract available
     
     
     
384. CULLARO G, Allegretti AS, Fenton C, Ge J, et al
     The association between mean arterial pressure and acute kidney injury reversal among decompensated cirrhosis patients.
     Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000858.
     PubMed     Abstract available
     
     
     
385. WIGG AJ, Narayana S, Woodman RJ, Adams LA, et al
     A randomized multicenter trial of a chronic disease management intervention for decompensated cirrhosis. The Australian Liver Failure (ALFIE) trial.
     Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000862.
     PubMed     Abstract available
     
     
     
386. MEROUEH C, Warasnhe K, Tizhoosh HR, Shah VH, et al
     Digital pathology and spatial omics in steatohepatitis: Clinical applications and discovery potentials.
     Hepatology. 2024 Mar 22. doi: 10.1097/HEP.0000000000000866.
     PubMed     Abstract available
     
     
     
387. JONES DE, Beuers U, Bonder A, Carbone M, et al
     Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?
     Hepatology. 2024 Mar 22. doi: 10.1097/HEP.0000000000000864.
     PubMed     Abstract available
     
     
     
388. STERLING RK, Asrani SK, Levine D, Duarte-Rojo A, et al
     AASLD Practice Guideline on non-invasive liver disease assessments of portal hypertension.
     Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000844.
     PubMed    
     
     
     
389. STERLING RK, Patel K, Duarte-Rojo A, Asrani SK, et al
     AASLD Practice Guideline on blood-based non-invasive liver disease assessments of hepatic fibrosis and steatosis.
     Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000845.
     PubMed    
     
     
     
390. STERLING RK, Duarte-Rojo A, Patel K, Asrani SK, et al
     AASLD Practice Guideline on imaging-based non-invasive liver disease assessments of hepatic fibrosis and steatosis.
     Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000843.
     PubMed    
     
     
     
391. ROCKEY DC, Alsawas M, Rojo-Duarte A, Patel K, et al
     Non-invasive liver disease assessment to identify portal hypertension: A systematic review supporting the AASLD Practice Guideline.
     Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000841.
     PubMed     Abstract available
     
     
     
392. DIETZ-FRICKE C, Degasperi E, Jachs M, Maasoumy B, et al
     Safety and efficacy of off-label bulevirtide monotherapy in HDV patients with decompensated Child-B cirrhosis - a real world case series.
     Hepatology. 2024 Mar 13. doi: 10.1097/HEP.0000000000000847.
     PubMed     Abstract available
     
     
     
393. MARCHETTI A, Pelusi S, Marella A, Malvestiti F, et al
     Impact of clonal hematopoiesis of indeterminate potential on hepatocellular carcinoma in individuals with steatotic liver disease.
     Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000839.
     PubMed     Abstract available
     
     
     
394. BU W, Sun X, Xue X, Geng S, et al
     Early onset of pathological polyploidization and cellular senescence in hepatocytes lacking RAD51 creates a pro-fibrotic and pro-tumorigenic inflammatory microenvironment.
     Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000821.
     PubMed     Abstract available
     
     
     
395. MUNOZ AE, Rodger EG
     Letter to the Editor: Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC.
     Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000846.
     PubMed    
     
     
     
396. SHARPTON S, Loomba R
     Response to Letter to the Editor: emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC.
     Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000848.
     PubMed    
     
     
     
397. GUO Q, Wang J, Wang G, Wang X, et al
     Letter to the Editor: Is right heart assessment vital for evaluating Terlipressin-related outcomes in Hepatorenal Syndrome-AKI?
     Hepatology. 2024 Mar 8. doi: 10.1097/HEP.0000000000000832.
     PubMed    
     
     
     
398. CHAPMAN B, Wong D, Sinclair M, Hey P, et al
     Reversing malnutrition and low muscle strength with targeted enteral feeding in patients awaiting liver transplant: A randomized controlled trial.
     Hepatology. 2024 Mar 8. doi: 10.1097/HEP.0000000000000840.
     PubMed     Abstract available
     
     
     
399. BERENGUER J, Aldamiz-Echevarria T, Hontanon V, Fanciulli C, et al
     Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV coinfected patients with advanced Fibrosis/Cirrhosis.
     Hepatology. 2024 Mar 7. doi: 10.1097/HEP.0000000000000838.
     PubMed     Abstract available
     
     
     
400. SEMMLER G, Hartl L, Mendoza YP, Simbrunner B, et al
     Simple blood tests to diagnose compensated advanced chronic liver disease and stratify risk of clinically significant portal hypertension.
     Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000829.
     PubMed     Abstract available
     
     
     
401. AMPUERO J, Lucena A, Berenguer M, Hernandez-Guerra M, et al
     Predictive factors for decompensating events in cirrhotic patients with primary biliary cholangitis under different lines of therapy.
     Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000826.
     PubMed     Abstract available
     
     
     
402. LAL BB, Alam S, Sibal A, Kumar K, et al
     Genotype correlates with clinical course and outcome of children with tight junction protein 2 (TJP2) deficiency-related cholestasis.
     Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000828.
     PubMed     Abstract available
     
     
     
403. ROY A, Kajal K, Izzy M, Sihag BK, et al
     Reply: Is right heart assessment vital for evaluating terlipressin-related outcomes in Hepatorenal Syndrome-AKI ?
     Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000833.
     PubMed    
     
     
     
404. KUMAR M, Venishetty S, Jindal A, Bihari C, et al
     Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis - a randomized controlled trial.
     Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000817.
     PubMed     Abstract available
     
     
     
405. 
     Erratum: An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations.
     Hepatology. 2024;79:E105.
     PubMed    
     
     
     
406. HOOFNAGLE JH, Doo E
     Letter to the Editor: A multi-society Delphi consensus statement on new fatty liver disease nomenclature.
     Hepatology. 2024;79:E91-E92.
     PubMed    
     
     
     
407. LAZARUS JV, Newsome PN, Francque SM, Kanwal F, et al
     Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature.
     Hepatology. 2024;79:E93-E94.
     PubMed    
     
     
     
408. BARMAN-AKSOZEN J, Minder AE, Schuppan D, Stolzel U, et al
     Letter to the Editor: Contrasting effect of iron supplementation in protoporphyria.
     Hepatology. 2024;79:E87-E88.
     PubMed    
     
     
     
409. LEVY C, Dickey AK, Anderson KE, Keel SB, et al
     Reply: Contrasting effect of iron supplementation in protoporphyria.
     Hepatology. 2024;79:E89-E90.
     PubMed    
     
     
     
410. NICOARA-FARCAU O, Han G, Rudler M, Angrisani D, et al
     Pre-emptive TIPS in high-risk acute variceal bleeding. An updated and revised individual patient data meta-analysis.
     Hepatology. 2024;79:624-635.
     PubMed     Abstract available
     
     
     
411. WANG F, Chen L, Kong D, Zhang X, et al
     Canonical Wnt signaling promotes HSC glycolysis and liver fibrosis through an LDH-A/HIF-1alpha transcriptional complex.
     Hepatology. 2024;79:606-623.
     PubMed     Abstract available
     
     
     
412. LEE BP, Dodge JL, Terrault NA
     National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature.
     Hepatology. 2024;79:666-673.
     PubMed     Abstract available
     
     
     
413. BARTEN TRM, Atsma F, van der Meer AJ, Gansevoort R, et al
     Higher need for polycystic liver disease therapy in female patients: Sex-specific association between liver volume and need for therapy.
     Hepatology. 2024;79:551-559.
     PubMed     Abstract available
     
     
     
414. LEDENKO M, Antwi SO, Patel T
     Geospatial analysis of cyanobacterial exposure and liver cancer in the contiguous United States.
     Hepatology. 2024;79:575-588.
     PubMed     Abstract available
     
     
     
415. LEVY C, Dickey AK, Wang B, Thapar M, et al
     Evidence-based consensus guidelines for the diagnosis and management of protoporphyria-related liver dysfunction in erythropoietic protoporphyria and X-linked protoporphyria.
     Hepatology. 2024;79:731-743.
     PubMed    
     
     
     
416. 
     Hepatology Highlights.
     Hepatology. 2024;79:525-526.
     PubMed    
     
     
     February 2024
417. WONG YJ, Teng M, Sim A, Thet HM, et al
     Full adherence to cirrhosis quality indicators is associated with lower mortality in acute variceal bleeding: Nationwide audit.
     Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000793.
     PubMed     Abstract available
     
     
     
418. HASSAN MM, Li D, Han Y, Byun J, et al
     Genome-wide association study identifies high-impact susceptibility loci for hepatocellular carcinoma in North America.
     Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000800.
     PubMed     Abstract available
     
     
     
419. ENGELSKIRCHER SA, Chen PC, Strunz B, Oltmanns C, et al
     Impending hepatocellular carcinoma diagnosis in cirrhotic patients after HCV cure features a natural killer cell signature.
     Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000804.
     PubMed     Abstract available
     
     
     
420. PENG Z, Wei G, Huang P, Matta H, et al
     ASK1/p38 axis inhibition blocks the release of mitochondrial "danger signals" from hepatocytes and suppresses progression to cirrhosis and liver cancer.
     Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000801.
     PubMed     Abstract available
     
     
     
421. HE B, Huang Z, Qin S, Peng P, et al
     Enhanced SLC35B2/SAV1 sulfation axis promotes tumor growth through inhibiting Hippo signaling in hepatocellular carcinoma.
     Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000783.
     PubMed     Abstract available
     
     
     
422. CALTHORPE L, Chiou SH, Rubin J, Huang CY, et al
     A modified hospital frailty risk score for patients with cirrhosis undergoing abdominal operations.
     Hepatology. 2024 Feb 19. doi: 10.1097/HEP.0000000000000794.
     PubMed     Abstract available
     
     
     
423. PREMKUMAR M, Kajal K, Izzy M, Sihag BK, et al
     Reply to 'liver, heart, and kidney crosstalk in cirrhosis: POCUS is the focus".
     Hepatology. 2024 Feb 16. doi: 10.1097/HEP.0000000000000792.
     PubMed    
     
     
     
424. PAPATHERODORIDIS G, Lampertico P
     Hepatocellular carcinoma risk in HBeAg-positive chronic hepatitis B patients under long-term nucleos(t)ide analogue therapy: New insights from Asia.
     Hepatology. 2024 Feb 16. doi: 10.1097/HEP.0000000000000796.
     PubMed    
     
     
     
425. ZHU M, Liu Z, Chen S, Luo Z, et al
     Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study.
     Hepatology. 2024 Feb 15. doi: 10.1097/HEP.0000000000000776.
     PubMed     Abstract available
     
     
     
426. PARK JG, Roh PR, Kang MW, Cho SW, et al
     Intrahepatic immunoglobulin a complex induces polarization of cancer-associated fibroblasts to matrix phenotypes in the tumor microenvironment of hepatocellular carcinoma.
     Hepatology. 2024 Feb 15. doi: 10.1097/HEP.0000000000000772.
     PubMed     Abstract available
     
     
     
427. DONGELMANS E, Erler N, Adam R, Nadalin S, et al
     Recent outcomes of liver transplantation for Budd Chiari Syndrome - a study of the European Liver Transplant Registry (ELTR) and affiliated centers.
     Hepatology. 2024 Feb 15. doi: 10.1097/HEP.0000000000000778.
     PubMed     Abstract available
     
     
     
428. AGRAWAL D, Ariga KK
     Liver, heart, and kidney crosstalk in cirrhosis: POCUS is the focus.
     Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000789.
     PubMed    
     
     
     
429. ALLEGRETTI AS, Patidar KR, Ma AT, Cullaro G, et al
     From past to present to future: Terlipressin and hepatorenal syndrome-acute kidney injury.
     Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000790.
     PubMed     Abstract available
     
     
     
430. MOCTEZUMA-VELAZQUEZ C, Wong YJ, Montano-Loza AJ
     Editorial: Promise and pitfalls of a natural killer cell signature for hepatocellular carcinoma detection in HCV patients with sustained virological response.
     Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000797.
     PubMed    
     
     
     
431. EHRENBAUER AF, Egge JFM, Gabriel MM, Tiede A, et al
     Comparison of six tests for diagnosing minimal hepatic encephalopathy and predicting clinical outcome - A prospective, observational study.
     Hepatology. 2024 Feb 13. doi: 10.1097/HEP.0000000000000770.
     PubMed     Abstract available
     
     
     
432. RINELLA ME, Castro Narro GE, Krag A, Terrault N, et al
     Reply: 'From NAFLD to MASLD: Promise and pitfalls of a new definition' dagger.
     Hepatology. 2024;79:E16-E17.
     PubMed    
     
     
     
433. CUSI K, Younossi Z, Roden M
     From NAFLD to MASLD: Promise and pitfalls of a new definition dagger.
     Hepatology. 2024;79:E13-E15.
     PubMed    
     
     
     
434. BALAKRISHNAN M, Rehm J
     A public health perspective on mitigating the global burden of chronic liver disease.
     Hepatology. 2024;79:451-459.
     PubMed     Abstract available
     
     
     
435. KHALID M, Khan ZM, Sheraz Kahloon A
     Letter to the Editor: NAFLD improves risk prediction of type 2 diabetes-With effect modification by sex and menopausal status.
     Hepatology. 2024;79:E18-E19.
     PubMed    
     
     
     
436. KIM Y, Chang Y, Ryu S, Wild SH, et al
     Reply: NAFLD improves risk prediction of type 2 diabetes-With effect modification by sex and menopausal status.
     Hepatology. 2024;79:E20-E21.
     PubMed    
     
     
     
437. BARR RG, Bolondi L
     Contrast-enhanced US for HCC: Finally out from the waiting list?
     Hepatology. 2024;79:267-268.
     PubMed    
     
     
     
438. LYSHCHIK A, Wessner CE, Bradigan K, Eisenbrey JR, et al
     Contrast-enhanced ultrasound liver imaging reporting and data system: clinical validation in a prospective multinational study in North America and Europe.
     Hepatology. 2024;79:380-391.
     PubMed     Abstract available
     
     
     
439. HUANG H, Tsui YM, Ho DW, Chung CY, et al
     LANCL1, a cell surface protein, promotes liver tumor initiation through FAM49B-Rac1 axis to suppress oxidative stress.
     Hepatology. 2024;79:323-340.
     PubMed     Abstract available
     
     
     
440. LAZARUS JV, Mark HE, Allen AM, Arab JP, et al
     A global action agenda for turning the tide on fatty liver disease.
     Hepatology. 2024;79:502-523.
     PubMed     Abstract available
     
     
     
441. MENG Z, Zhou L, Hong S, Qiu X, et al
     Myeloid-specific ablation of Basp1 ameliorates diet-induced NASH in mice by attenuating pro-inflammatory signaling.
     Hepatology. 2024;79:409-424.
     PubMed     Abstract available
     
     
     
442. SINHA S, Hassan N, Schwartz RE
     Organelle stress and alterations in interorganelle crosstalk during liver fibrosis.
     Hepatology. 2024;79:482-501.
     PubMed     Abstract available
     
     
     
443. 
     Hepatology Highlights.
     Hepatology. 2024;79:255-256.
     PubMed    
     
     
     
444. 
     Hepatology Highlights.
     Hepatology. 2024;79:255-256.
     PubMed    
     
     
     January 2024
445. 
     Erratum: Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia.
     Hepatology. 2024 Jan 29. doi: 10.1097/HEP.0000000000000730.
     PubMed    
     
     
     
446. WANG Y, Wang X, Bai B, Shaha A, et al
     Targeting Src SH3 domain-mediated glycolysis of hepatic stellate cells suppresses transcriptome, myofibroblastic activation, and colorectal liver metastasis.
     Hepatology. 2024 Jan 24. doi: 10.1097/HEP.0000000000000763.
     PubMed     Abstract available
     
     
     
447. XIA Y, Wang Y, Xiong Q, He J, et al
     Neutrophil extracellular traps promote MASH fibrosis by metabolic reprogramming of hepatic stellate cells.
     Hepatology. 2024 Jan 24. doi: 10.1097/HEP.0000000000000762.
     PubMed     Abstract available
     
     
     
448. 
     Hepatology highlights.
     Hepatology. 2024 Jan 23. doi: 10.1097/HEP.0000000000000742.
     PubMed    
     
     
     
449. NAKAGAWA H, Lin A
     The translation of oncogenic mRNAs regulated by pseudouridylation: A new player in hepatocellular carcinoma.
     Hepatology. 2024 Jan 22. doi: 10.1097/HEP.0000000000000761.
     PubMed    
     
     
     
450. NIEMIETZ P, Peiseler M, Kohlhepp M, Horn P, et al
     C-C chemokine receptor type 7 (CCR7) regulates hepatic CD8+ T cell homeostasis and response to acute liver injury.
     Hepatology. 2024 Jan 17. doi: 10.1097/HEP.0000000000000757.
     PubMed     Abstract available
     
     
     
451. TRIPODI A, Primignani M, D'Ambrosio R, Tosetti G, et al
     Reappraisal of the conventional hemostasis tests as predictors of perioperative bleeding in the era of rebalanced hemostasis in cirrhosis.
     Hepatology. 2024 Jan 12. doi: 10.1097/HEP.0000000000000756.
     PubMed     Abstract available
     
     
     
452. 
     Hepatology Highlights.
     Hepatology. 2024;79:1-2.
     PubMed    
     
     
     
453. BARGELLINI I, Rimassa L, Masi G
     SIRT and chemotherapy in unresectable iCCA: Ready to take off.
     Hepatology. 2024;79:9-11.
     PubMed    
     
     
     
454. EMANUELE E, Minoretti P
     Letter to the Editor: NAFLD, MAFLD or MASLD? Cut the Gordian knot with "Ludwig disease".
     Hepatology. 2024;79:E4.
     PubMed    
     
     
     
455. NEWSOME P, Rinella ME, Lazarus JV, Terrault N, et al
     Reply: NAFLD, MAFLD, or MASLD? Cut the Gordian knot with "Ludwig disease".
     Hepatology. 2024;79:E5-E6.
     PubMed    
     
     
     
456. ROWE IA
     Prediction of outcomes in patients with acute variceal bleeding.
     Hepatology. 2024;79:15-17.
     PubMed    
     
     
     
457. WANG CC, Cheng YM, Kao JH
     Letter to the Editor: Statement of steatotic liver disease-A great leap toward the global standardization.
     Hepatology. 2024;79:E7-E8.
     PubMed    
     
     
     
458. GARCIA-CRIADO A, Bruix J
     Screening for liver cancer: The good, the bad, and the ugly.
     Hepatology. 2024;79:12-14.
     PubMed    
     
     
     
459. CORPECHOT C, Lemoinne S, Soret PA, Hansen B, et al
     Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
     Hepatology. 2024;79:39-48.
     PubMed     Abstract available
     
     
     
460. LEE EW, Eghtesad B, Garcia-Tsao G, Haskal ZJ, et al
     AASLD Practice Guidance on the use of TIPS, variceal embolization, and retrograde transvenous obliteration in the management of variceal hemorrhage.
     Hepatology. 2024;79:224-250.
     PubMed    
     
     
     
461. 
     Hepatology Highlights.
     Hepatology. 2024;79:1-2.
     PubMed    
     
     
     December 2023
462. HOFER BS, Brusilovskaya K, Simbrunner B, Balcar L, et al
     Decreased platelet activation predicts hepatic decompensation and mortality in patients with cirrhosis.
     Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000740.
     PubMed     Abstract available
     
     
     
463. VAJRO P, Mandato C
     Letter to the Editor: More on Non-Alcohol/Non-Metabolic Dysfunction-Associated Steatohepatitis.
     Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000734.
     PubMed    
     
     
     
464. JENG WJ, Chien RN, Liaw YF
     Reply: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game?
     Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000737.
     PubMed    
     
     
     
465. CORPECHOT C, Lemoinne S, Soret PA, Chazouilleres O, et al
     Reply: Improving access to transient elastography data for Real-World Prognostic Applications in primary biliary cholangitis.
     Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000746.
     PubMed    
     
     
     
466. WIEGAND J, Franke A, Stein K, Trautwein C, et al
     Letter to the Editor: Improving access to transient elastography data for real-world prognostic applications in primary biliary cholangitis.
     Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000744.
     PubMed    
     
     
     
467. WATT KD, Khan MQ
     Reply to "more on non-alcohol/non-metabolic dysfunction-associated steatohepatitis".
     Hepatology. 2023 Dec 26. doi: 10.1097/HEP.0000000000000739.
     PubMed    
     
     
     
468. CHEN J, Tu T, Cohen C, Wang S, et al
     Letter to the Editor: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game?
     Hepatology. 2023 Dec 26. doi: 10.1097/HEP.0000000000000732.
     PubMed    
     
     
     
469. ZABRANSKY DJ, Yarchoan M, Ho WJ
     Reply: The Hepa 1-6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy.
     Hepatology. 2023 Dec 26. doi: 10.1097/HEP.0000000000000738.
     PubMed    
     
     
     
470. LU T, Zhang J, Li H, Li G, et al
     Letter to the Editor: The Hepa 1-6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy.
     Hepatology. 2023 Dec 25. doi: 10.1097/HEP.0000000000000733.
     PubMed    
     
     
     
471. KREMER AE, Mayo MJ, Hirschfield GM, Levy C, et al
     Seladelpar treatment reduces interleukin-31 and pruritus in patients with primary biliary cholangitis.
     Hepatology. 2023 Dec 20. doi: 10.1097/HEP.0000000000000728.
     PubMed     Abstract available
     
     
     
472. RATZIU V, Francque S, Behling CA, Cejvanovic V, et al
     Artificial intelligence scoring of liver biopsies in a phase ii trial of semaglutide in non-alcoholic steatohepatitis.
     Hepatology. 2023 Dec 19. doi: 10.1097/HEP.0000000000000723.
     PubMed     Abstract available
     
     
     
473. VOGEL A, Grant RC, Meyer T, Sapisochin G, et al
     Adjuvant and neoadjuvant therapies for hepatocellular carcinoma.
     Hepatology. 2023 Dec 18. doi: 10.1097/HEP.0000000000000726.
     PubMed     Abstract available
     
     
     
474. SIDDIQUI MS, Muthiah M, Satapathy SK, Patidar K, et al
     Defining an approach for therapeutic strategies in metabolic dysfunction-associated steatotic liver disease after liver transplantation.
     Hepatology. 2023 Dec 13. doi: 10.1097/HEP.0000000000000720.
     PubMed     Abstract available
     
     
     
475. SCHULZE RJ, Strom SC, Nyberg SL
     From pain to gain: Leveraging acetaminophen in hepatocyte transplantation for phenylketonuria.
     Hepatology. 2023 Dec 12. doi: 10.1097/HEP.0000000000000713.
     PubMed    
     
     
     
476. YU S, Liu X, Xu Y, Pan L, et al
     m6A-mediated gluconeogenic enzyme PCK1 upregulation protects against hepatic ischemia-reperfusion injury.
     Hepatology. 2023 Dec 12. doi: 10.1097/HEP.0000000000000716.
     PubMed     Abstract available
     
     
     
477. YIN C, Zhang C, Wang Y, Liu G, et al
     ALDOB/KAT2A interactions epigenetically modulate TGF-beta expression and T cell functions in hepatocellular carcinogenesis.
     Hepatology. 2023 Dec 5. doi: 10.1097/HEP.0000000000000704.
     PubMed     Abstract available
     
     
     
478. CHAN FF, Yuen VW, Shen J, Chin DW, et al
     Inhibition of CAF-1 histone chaperone complex triggers cytosolic DNA and dsRNA sensing pathways and induces intrinsic immunity of hepatocellular carcinoma.
     Hepatology. 2023 Dec 5. doi: 10.1097/HEP.0000000000000709.
     PubMed     Abstract available
     
     
     
479. MALHI H, Brown RS Jr, Lim JK, Reau N, et al
     Precipitous changes in nomenclature and definitions-NAFLD becomes SLD: Implications for and expectations of AASLD journals.
     Hepatology. 2023;78:1680-1681.
     PubMed    
     
     
     
480. RINELLA ME, Lazarus JV, Ratziu V, Francque SM, et al
     A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
     Hepatology. 2023;78:1966-1986.
     PubMed     Abstract available
     
     
     
481. DESAI AP, Madathanapalli A, Tang Q, Orman ES, et al
     PROMIS Profile-29 is a valid instrument with distinct advantages over legacy instruments for measuring the quality of life in chronic liver disease.
     Hepatology. 2023;78:1788-1799.
     PubMed     Abstract available
     
     
     
482. ABERG F
     Letter to the Editor: ELF in the risk stratification of NAFLD-Are the ELF thresholds suggested by the AASLD guidelines appropriate?
     Hepatology. 2023;78:E101-E102.
     PubMed    
     
     
     
483. RINELLA ME, Terrault N, Neuschwander-Tetri B, Loomba R, et al
     Reply: ELF in the risk stratification of NAFLD-Are the ELF thresholds suggested by the AASLD guidelines appropriate?
     Hepatology. 2023;78:E103-E104.
     PubMed    
     
     
     
484. ZHANG X, Yip TC, Tse YK, Hui VW, et al
     Duration of type 2 diabetes and liver-related events in nonalcoholic fatty liver disease: A landmark analysis.
     Hepatology. 2023;78:1816-1827.
     PubMed     Abstract available
     
     
     
485. GAO R, Li Y, Xu Z, Zhang F, et al
     Mitochondrial pyruvate carrier 1 regulates fatty acid synthase lactylation and mediates treatment of nonalcoholic fatty liver disease.
     Hepatology. 2023;78:1800-1815.
     PubMed     Abstract available
     
     
     
486. 
     Erratum: Interleukin-18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis.
     Hepatology. 2023;78:E110.
     PubMed    
     
     
     
487. 
     Erratum: Diabetes and cirrhosis: Current concepts on diagnosis and management.
     Hepatology. 2023;78:E108.
     PubMed    
     
     
     
488. 
     Erratum: Inhibition of mPGES-2 ameliorates non-alcoholic steatohepatitis by activating NR1D1 via heme.
     Hepatology. 2023;78:E107.
     PubMed    
     
     
     
489. MAIWALL R, Piano S, Singh V, Caraceni P, et al
     Determinants of clinical response to empirical antibiotic treatment in patients with cirrhosis and bacterial and fungal infections- Results from the ICA 'Global study' [EABCIR-Global Study].
     Hepatology. 2023 Dec 1. doi: 10.1097/HEP.0000000000000653.
     PubMed     Abstract available
     
     
     
490. 
     Ending stigmatizing language in alcohol and liver disease: A liver societies' statement dagger.
     Hepatology. 2023;78:1682-1683.
     PubMed    
     
     
     November 2023
491. HU YX, Diao LT, Hou YR, Lv G, et al
     PUS1 promotes hepatocellular carcinoma via mRNA pseudouridylation to enhance the translation of oncogenic mRNAs.
     Hepatology. 2023 Nov 28. doi: 10.1097/HEP.0000000000000702.
     PubMed     Abstract available
     
     
     
492. PREMKUMAR M, Kajal K, Reddy KR, Izzy M, et al
     Evaluation of terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury using point-of-care echocardiography.
     Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000691.
     PubMed     Abstract available
     
     
     
493. MICHALOPOULOS GK
     Hepatocytes of mice and men: Different regenerative signals?
     Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000693.
     PubMed    
     
     
     
494. KE L, Rui Z, Fukai W, Yunzheng Z, et al
     Single-cell dissection of the multicellular ecosystem and molecular features underlying microvascular invasion in hepatocellular carcinoma.
     Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000673.
     PubMed     Abstract available
     
     
     
495. 
     February 2024 Hepatology Highlights.
     Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000681.
     PubMed    
     
     
     
496. VAN DER MEEREN PE, Frederik de Wilde R, Sprengers D, IJzermans JNM, et al
     Benefit and harm of waiting time in liver transplantation for HCC.
     Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000668.
     PubMed     Abstract available
     
     
     
497. LIU N, Tian J, Steer CJ, Han Q, et al
     MicroRNA-206-3p suppresses hepatic lipogenesis and cholesterol synthesis while driving cholesterol efflux.
     Hepatology. 2023 Nov 9. doi: 10.1097/HEP.0000000000000672.
     PubMed     Abstract available
     
     
     
498. KARVELLAS CJ, Bajaj JS, Kamath PS, Napolitano L, et al
     AASLD Practice guidance on Acute-on-chronic liver failure and the management of critically Ill patients with cirrhosis.
     Hepatology. 2023 Nov 9. doi: 10.1097/HEP.0000000000000671.
     PubMed    
     
     
     
499. QASIM KHAN M, Hassan S, Lizaola-Mayo BC, Bhat M, et al
     Navigating the 'Specific Etiology' steatohepatitis category: Evaluation & management of non-alcohol/non-metabolic dysfunction-associated steatohepatitis.
     Hepatology. 2023 Nov 7. doi: 10.1097/HEP.0000000000000674.
     PubMed    
     
     
     
500. BRENNER DA
     Alternatives to animal testing to assess NASH drugs and hepatotoxicity.
     Hepatology. 2023 Nov 6. doi: 10.1097/HEP.0000000000000669.
     PubMed     Abstract available
     
     
     
501. SCHERR AL, Nader L, Xu K, Elssner C, et al
     Etiology-independent activation of the LTbeta-LTbetaR-RELB axis drives aggressiveness and predicts poor prognosis in Hepatocellular carcinoma.
     Hepatology. 2023 Nov 2. doi: 10.1097/HEP.0000000000000657.
     PubMed     Abstract available
     
     
     
502. D'AMICO G, Zipprich A, Villanueva C, Sorda JA, et al
     Further decompensation in cirrhosis. Results of a large multicenter cohort study supporting Baveno VII statements.
     Hepatology. 2023 Nov 2. doi: 10.1097/HEP.0000000000000652.
     PubMed     Abstract available
     
     
     
503. RINELLA ME, Terrault N, Neuschwander-Tetri B, Loomba R, et al
     Reply: People living with HIV and NAFLD and updated guidance on NAFLD screening.
     Hepatology. 2023;78:E91-E92.
     PubMed    
     
     
     
504. ARIAS-LOSTE MT, Crespo J, Iruzubieta P
     Letter to the Editor: Updated guidance on NAFLD screening.
     Hepatology. 2023;78:E89-E90.
     PubMed    
     
     
     
505. SEBASTIANI G, Milic J, Tsochatzis EA, Marzolini C, et al
     Letter to the Editor: People living with HIV and NAFLD-A population left behind in the global effort for liver fibrosis screening?
     Hepatology. 2023;78:E87-E88.
     PubMed    
     
     
     
506. YANG Z, Ding WX
     The pre-mRNA alternative splicing regulated by SRPK2: A new player in alcohol-associated liver disease?
     Hepatology. 2023;78:1329-1331.
     PubMed    
     
     
     
507. LAZARUS JV, Kopka CJ, Younossi ZM, Allen AM, et al
     It is time to expand the fatty liver disease community of practice.
     Hepatology. 2023;78:1325-1328.
     PubMed    
     
     
     
508. TILG H, Adolph TE, Tacke F
     Therapeutic modulation of the liver immune microenvironment.
     Hepatology. 2023;78:1581-1601.
     PubMed     Abstract available
     
     
     
509. NIKNEJAD N, Fox D, Burwinkel JL, Zarrin-Khameh N, et al
     ASO silencing of a glycosyltransferase, Poglut1 , improves the liver phenotypes in mouse models of Alagille syndrome.
     Hepatology. 2023;78:1337-1351.
     PubMed     Abstract available
     
     
     
510. WU Q, Pan C, Zhou Y, Wang S, et al
     Targeting neuropilin-1 abolishes anti-PD-1-upregulated regulatory T cells and synergizes with 4-1BB agonist for liver cancer treatment.
     Hepatology. 2023;78:1402-1417.
     PubMed     Abstract available
     
     
     
511. SONG Y, Wei J, Li R, Fu R, et al
     Tyrosine kinase receptor B attenuates liver fibrosis by inhibiting TGF-beta/SMAD signaling.
     Hepatology. 2023;78:1433-1447.
     PubMed     Abstract available
     
     
     
512. CHIU YT, Husain A, Sze KM, Ho DW, et al
     Midline 1 interacting protein 1 promotes cancer metastasis through FOS-like 1-mediated matrix metalloproteinase 9 signaling in HCC.
     Hepatology. 2023;78:1368-1383.
     PubMed     Abstract available
     
     
     
513. YANG F, Hilakivi-Clarke L, Shaha A, Wang Y, et al
     Metabolic reprogramming and its clinical implication for liver cancer.
     Hepatology. 2023;78:1602-1624.
     PubMed     Abstract available
     
     
     
514. LEE CM, Yoon EL, Kim M, Kang BK, et al
     Prevalence, distribution and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings.
     Hepatology. 2023 Nov 1. doi: 10.1097/HEP.0000000000000664.
     PubMed     Abstract available
     
     
     
515. BRAILLON A, Naudet F
     Letter to the Editor: Medications promoting abstinence in alcohol-associated cirrhosis.
     Hepatology. 2023 Nov 1. doi: 10.1097/HEP.0000000000000656.
     PubMed    
     
     
     October 2023
516. JENG WJ, Chien RN, Liaw YF
     Reply: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis.
     Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000662.
     PubMed    
     
     
     
517. DENG R, Wang Z, Liu Y, Sun J, et al
     Letter to the Editor: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis.
     Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000654.
     PubMed    
     
     
     
518. GRATACOS-GINES J, Lopez-Pelayo H, Pose E
     Reply: Medications promoting abstinence in alcohol-associated cirrhosis.
     Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000660.
     PubMed    
     
     
     
519. SELLERS ZM, Assis DN, Paranjape SM, Sathe M, et al
     Cystic fibrosis screening, evaluation and management of hepatobiliary disease consensus recommendations.
     Hepatology. 2023 Oct 26. doi: 10.1097/HEP.0000000000000646.
     PubMed     Abstract available
     
     
     
520. SONG Y, Ye T, Roberts LR, Larson NB, et al
     Randomization in hepatology: A review of principles, opportunities, and challenges.
     Hepatology. 2023 Oct 24. doi: 10.1097/HEP.0000000000000649.
     PubMed     Abstract available
     
     
     
521. KAPLAN DE, Bosch J, Ripoll C, Thiele M, et al
     AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis.
     Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000647.
     PubMed    
     
     
     
522. YANG T, Qu X, Wang X, Xu D, et al
     Macrophage STING-YAP axis controls hepatic steatosis by promoting autophagic degradation of lipid droplets.
     Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000638.
     PubMed     Abstract available
     
     
     
523. CHANG CW, Chen YS, Huang CH, Lin CH, et al
     A genetic basis of mitochondrial DNAJA3 in nonalcoholic steatohepatitis-related hepatocellular carcinoma.
     Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000637.
     PubMed     Abstract available
     
     
     
524. OLIVA-VILARNAU N, Beusch CM, Sabatier P, Sakaraki E, et al
     Wnt/beta-catenin and NFkappaB signaling synergize to trigger growth-factor-free regeneration of adult primary human hepatocytes.
     Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000648.
     PubMed     Abstract available
     
     
     
525. CAMPANI C, Vallot A, Ghannouchi H, Allaire M, et al
     Impact of radiological response and pattern of progression in patients with hepatocellular carcinoma treated by atezolizumab- bevacizumab.
     Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000636.
     PubMed     Abstract available
     
     
     
526. GISH RG, Wong RJ, Di Tanna GL, Kaushik A, et al
     Association between hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis.
     Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000642.
     PubMed     Abstract available
     
     
     
527. DONGELMANS EJ, Sonneveld MJ, Janssen HLA
     Letter to the Editor: Benefits of stopping therapy in cirrhotic hepatitis B patients, true effect or residual confounding?
     Hepatology. 2023 Oct 20. doi: 10.1097/HEP.0000000000000639.
     PubMed    
     
     
     
528. LIAW YF, Jeng WJ, Chien RN
     Reply: Benefits of stopping therapy in cirrhotic hepatitis B patients, true effect or residual confounding?
     Hepatology. 2023 Oct 20. doi: 10.1097/HEP.0000000000000641.
     PubMed    
     
     
     
529. 
     Erratum: AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.
     Hepatology. 2023 Oct 16. doi: 10.1097/HEP.0000000000000621.
     PubMed    
     
     
     
530. VONADA A, Wakefield L, Martinez M, Harding CO, et al
     Complete correction of murine phenylketonuria by selection-enhanced hepatocyte transplantation.
     Hepatology. 2023 Oct 12. doi: 10.1097/HEP.0000000000000631.
     PubMed     Abstract available
     
     
     
531. CHEN P, Dong Z, Zhu W, Chen J, et al
     Noncanonical regulation of HOIL-1 on cancer stemness and sorafenib resistance identifies pixantrone as a novel therapeutic agent for hepatocellular carcinoma.
     Hepatology. 2023 Oct 11. doi: 10.1097/HEP.0000000000000623.
     PubMed     Abstract available
     
     
     
532. MA S, Chew V
     Unlocking the immune microenvironment of non-alcoholic steatohepatitis-associated hepatocellular carcinoma.
     Hepatology. 2023 Oct 9. doi: 10.1097/HEP.0000000000000626.
     PubMed    
     
     
     
533. THIELE M, Johansen S, Israelsen M, Trebicka J, et al
     Non-invasive assessment of hepatic decompensation.
     Hepatology. 2023 Oct 6. doi: 10.1097/HEP.0000000000000618.
     PubMed     Abstract available
     
     
     
534. PENNISI G, Enea M, Romero-Gomez M, Bugianesi E, et al
     Risk of liver-related events in metabolic dysfunction-associated steatohepatitis (MASH) patients with fibrosis: A comparative analysis of various risk stratification criteria.
     Hepatology. 2023 Oct 2. doi: 10.1097/HEP.0000000000000616.
     PubMed     Abstract available
     
     
     
535. XANTHAKOS S
     Rising tide of NAFLD in youth: A warning bell and call to action.
     Hepatology. 2023;78:1017-1019.
     PubMed    
     
     
     
536. ANTON A, Shalaby S, Hernandez-Gea V
     Coagulation meets senescence in NASH!
     Hepatology. 2023;78:1023-1025.
     PubMed    
     
     
     
537. YONEDA M, Nakajima A
     The role of MRI technology in liver evaluation for NAFLD patients: Advancements and opportunities.
     Hepatology. 2023;78:1020-1022.
     PubMed    
     
     
     
538. CHEN W, Sun Y, Chen S, Ge X, et al
     Matrisome gene-based subclassification of patients with liver fibrosis identifies clinical and molecular heterogeneities.
     Hepatology. 2023;78:1118-1132.
     PubMed     Abstract available
     
     
     
539. LI J, Lu X, Zhu Z, Kalutkiewicz KJ, et al
     Head-to-head comparison of magnetic resonance elastography-based liver stiffness, fat fraction, and T1 relaxation time in identifying at-risk NASH.
     Hepatology. 2023;78:1200-1208.
     PubMed     Abstract available
     
     
     
540. KIM ??? WR, Iwakiri ???? Y, Lok ??? ASF
     What is in a name? Toward culturally sensitive nomenclature for liver disease in the east and west.
     Hepatology. 2023;78:1032-1034.
     PubMed    
     
     
     
541. MINCIUNA I, Gallage S, Heikenwalder M, Zelber-Sagi S, et al
     Intermittent fasting-the future treatment in NASH patients?
     Hepatology. 2023;78:1290-1305.
     PubMed     Abstract available
     
     
     
542. CALZADILLA-BERTOT L, Jeffrey GP, Wang Z, Huang Y, et al
     Predicting liver-related events in NAFLD: A predictive model.
     Hepatology. 2023;78:1240-1251.
     PubMed     Abstract available
     
     
     
543. SEIMIYA T, Otsuka M, Fujishiro M
     Overcoming T-cell exhaustion: New therapeutic targets in HCC immunotherapy.
     Hepatology. 2023;78:1009-1011.
     PubMed    
     
     
     
544. 
     Erratum: Down-Regulation of the Cyclin-Dependent kinase inhibitor p57 is mediated by Jab1/Csn5 in hepatocarcinogenesis.
     Hepatology. 2023;78:E85.
     PubMed    
     
     
     
545. STRAVITZ RT, Fontana RJ, Karvellas C, Durkalski V, et al
     Future directions in acute liver failure.
     Hepatology. 2023;78:1266-1289.
     PubMed     Abstract available
     
     
     
546. HARTMANN P, Zhang X, Loomba R, Schnabl B, et al
     Global and national prevalence of nonalcoholic fatty liver disease in adolescents: An analysis of the global burden of disease study 2019.
     Hepatology. 2023;78:1168-1181.
     PubMed     Abstract available
     
     
     
547. KOTULKAR M, Paine-Cabrera D, Abernathy S, Robarts DR, et al
     Role of HNF4alpha-cMyc interaction in liver regeneration and recovery after acetaminophen-induced acute liver injury.
     Hepatology. 2023;78:1106-1117.
     PubMed     Abstract available
     
     
     
548. DE ANGELIS RIGOTTI F, Wiedmann L, Hubert MO, Vacca M, et al
     Semaphorin 3C exacerbates liver fibrosis.
     Hepatology. 2023;78:1092-1105.
     PubMed     Abstract available
     
     
     September 2023
549. NAHON P, Layese R, Ganne-Carrie N, Moins C, et al
     The clinical and financial burden of nonhepatocellular carcinoma focal lesions detected during surveillance of patients with cirrhosis.
     Hepatology. 2023 Sep 29. doi: 10.1097/HEP.0000000000000615.
     PubMed     Abstract available
     
     
     
550. LI M, Wang L, Cong L, Wong CC, et al
     Spatial proteomics of immune microenvironment in nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
     Hepatology. 2023 Sep 21. doi: 10.1097/HEP.0000000000000591.
     PubMed     Abstract available
     
     
     
551. RINELLA ME, Lieu HD, Kowdley KV, Goodman ZD, et al
     A randomized, double-blind, placebo-controlled trial of Aldafermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis.
     Hepatology. 2023 Sep 21. doi: 10.1097/HEP.0000000000000607.
     PubMed     Abstract available
     
     
     
552. ZHAO X, Kotha S, Nayyar D, Ma X, et al
     Physiologic changes in the hepatopulmonary syndrome before and after liver transplant: A longitudinal and predictor analysis.
     Hepatology. 2023 Sep 21. doi: 10.1097/HEP.0000000000000605.
     PubMed     Abstract available
     
     
     
553. FAILLI M, Demir S, Del Rio-Alvarez A, Carrillo-Reixach J, et al
     Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological response.
     Hepatology. 2023 Sep 20. doi: 10.1097/HEP.0000000000000601.
     PubMed     Abstract available
     
     
     
554. GELLERT-KRISTENSEN H, Bojesen SE, Tybjaerg-Hansen A, Stender S, et al
     Telomere length and risk of cirrhosis, hepatocellular carcinoma, and cholangiocarcinoma in 63,272 individuals from the general population.
     Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000608.
     PubMed     Abstract available
     
     
     
555. WATT KD, Paul S, Khan MQ, Siddiqui M, et al
     Obesity management for the hepatologist - what to do, how to do it and why.
     Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000598.
     PubMed     Abstract available
     
     
     
556. CHEN S, Liao C, Hu H, Liao J, et al
     Hypoxia-driven tumor stromal remodeling and immunosuppressive microenvironment in scirrhous hepatocellular carcinoma.
     Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000599.
     PubMed     Abstract available
     
     
     
557. MAESTRI E, Kedei N, Khatib S, Forgues M, et al
     Spatial proximity of Tumor-Immune interactions predicts patient outcome in hepatocellular carcinoma.
     Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000600.
     PubMed     Abstract available
     
     
     
558. ZHUANG Y, Ortega-Ribera M, Thevkar Nagesh P, Joshi R, et al
     Bile acid-induced IRF3 phosphorylation mediates cell death, inflammatory responses and fibrosis in cholestasis-induced liver and kidney injury via regulation of ZBP1.
     Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000611.
     PubMed     Abstract available
     
     
     
559. 
     December 2023 Hepatology Highlights.
     Hepatology. 2023 Sep 14. doi: 10.1097/HEP.0000000000000594.
     PubMed    
     
     
     
560. WU T, Chen X, Xu K, Dai C, et al
     LIM domain only 7 negatively controls non-alcoholic steatohepatitis in the setting of hyperlipidaemia.
     Hepatology. 2023 Sep 1. doi: 10.1097/HEP.0000000000000585.
     PubMed     Abstract available
     
     
     August 2023
561. GE J, Fontil V, Ackerman S, Pletcher MJ, et al
     Clinical decision support and electronic interventions to improve care quality in chronic liver diseases and cirrhosis.
     Hepatology. 2023 Aug 23. doi: 10.1097/HEP.0000000000000583.
     PubMed     Abstract available
     
     
     
562. PEISELER M, Tacke F
     Bile duct-associated macrophages enter the spotlight in inflammatory cholestatic liver disease.
     Hepatology. 2023 Aug 22. doi: 10.1097/HEP.0000000000000576.
     PubMed    
     
     
     
563. BOWLUS CL, Levy C
     Optimizing treatment of primary biliary cholangitis: Is good, good enough?
     Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000556.
     PubMed    
     
     
     
564. DE MUYNCK K, Heyerick L, De Ponti FF, Vanderborght B, et al
     Osteopontin characterizes bile duct associated macrophages and correlates with liver fibrosis severity in primary sclerosing cholangitis.
     Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000557.
     PubMed     Abstract available
     
     
     
565. 
     August Hepatology Highlights.
     Hepatology. 2023;78:369-370.
     PubMed    
     
     
     July 2023
566. 
     July 2023 Hepatology Highlights.
     Hepatology. 2023;78:1-2.
     PubMed    
     
     
     June 2023
567. SOKOL RJ, Gonzales EM, Kamath BM, Baker A, et al
     Predictors of 6-year event-free survival in alagille syndrome patients treated with maralixibat, an ileal bile acid transporter inhibitor.
     Hepatology. 2023 Jun 7. doi: 10.1097/HEP.0000000000000502.
     PubMed     Abstract available
     
     
     May 2023
568. 
     May 2023 Hepatology Highlights.
     Hepatology. 2023;77:1461-1462.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.